Skip to main content
SpringerLink
Log in
Book cover

Replacement of Renal Function by Dialysis pp 750–820Cite as

Drug Dosage in Dialysis Patients

  • Chapter

Abstract

The elimination of most drugs and their metabolites is completely or partially dependent on renal excretion. Pharmacologie action is related to free drug concentration achieved at tissue receptor sites. To avert drug accumulation and possible toxicity, proper consideration must be taken when prescribing dosage regimens for patients with renal failure. Awareness of basic pharmacokinetic and pharmacodynamic principles is necessary to understand the alterations in drug metabolism and elimination that occur in uremia (1, 2). Typically, dialysis patients receive more than eight different medications (2). Adverse drug reactions occur more frequently in patients with renal insufficiency compared to nonazotemic hospitalized patient (3). This chapter addresses the principles relating to rational drug therapy in dialysis patients

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Golper TA, Bennett WM: Altering drug dose in liver and kidney diseases, in Handbook of Drug Therapy in Liver and Kidney Disease, edited by Schrier R, Gambertoglio J. Boston, Little Brown, 1991, p 1

    Google Scholar 

  2. Bennett WM: Adjustment of drug dosage in patiejnts with renal insufficiency. in Textbookof Internal Medicine, edited by Kelley WM, New York, Lippincott, 1991. p 763

    Google Scholar 

  3. Jick H: Adverse drug effects in relation to renal function. Am J Med 62: 514, 1977

    PubMed  CAS  Google Scholar 

  4. Benet LZ, Massoud N: Pharmacokinetics. in Pharmacokinetic Basis for Drug Treatment, edited by Benet LZ, Massoud N, Gambertoglio JG, New York, Raven, 1984, p 1

    Google Scholar 

  5. Ritschel WA: Handbook of Basic Pharmacokinetics — Including Clinical Applications, 3rd Edition. Hmilton, Drug Intelligence Press Inc, 1986, p 163

    Google Scholar 

  6. Sachs EF, Hurwitz FJ, Bloch HM, Milne FJ: Pancreatic exocrine hypofunction in the wasting syndrome of end-stage renal disease. Am J Gastroenterol 78, 170, 1983

    PubMed  CAS  Google Scholar 

  7. Ochs HR, Greenblatt DJ, Bodem G, Dengler HJ: Disease-related alterations in cardiac glycoside disposition. Clin Pharmacokinet 7: 434, 1982

    PubMed  CAS  Google Scholar 

  8. Gibaldi M: Drug distribution in renal failure. Am J Med 62:471, 1977

    PubMed  CAS  Google Scholar 

  9. Reidenberg MM: The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. Am J Med 62: 466, 1977

    PubMed  CAS  Google Scholar 

  10. Gulyassy PF, Depner TA: Impaired binding of drugs and endogenous ligands in renal disease. Am J Kidney Dis 2: 578, 1983

    PubMed  CAS  Google Scholar 

  11. McNamara PJ, Lalka D, Gibaldi M: Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med 98: 730, 1981

    PubMed  CAS  Google Scholar 

  12. Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S: Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int 33: 996, 1988

    PubMed  CAS  Google Scholar 

  13. Boobis SW: Alteration of plasma albumin in relation to decreased drug binding in uremia. Clin Pharmacol Ther 22: 147, 1977

    PubMed  CAS  Google Scholar 

  14. Maher JF: Principles of dialysis and dialysis of drugs. Am J Med 62: 475, 1977

    PubMed  CAS  Google Scholar 

  15. Golper TA, Bennett WM: Drug visage in dialysis patients, in Clinical Dialysis, 2nd Edition, edited by Nissenson A, Fine R, Gentile D, Norwalk, Appleton-Lange, 1988, p 608

    Google Scholar 

  16. Vos MC, Vincent HH, Yzerman EPF, Vogel M, Mouton JW: Drug cleared by continuous hemodiafiltration (CAVHD): results with the AN69 capillary hemofilter and recommended dose adjustments for seven antibiotics. Drug Invest 1994. In press

    Google Scholar 

  17. Tillement JP, Lhoste F, Findicelli TF: Diseases and drug protein binding. Clin Pharmacokinet 3: 144, 1978

    PubMed  CAS  Google Scholar 

  18. Lee CS, Marbury TC: Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetical considerations. Clin Pharmacokinet 9: 42, 1984

    PubMed  CAS  Google Scholar 

  19. Piafsky KM: Disease induced changes in the serum binding of basic drugs. Clin Pharmacokinet 5: 246, 1980

    PubMed  CAS  Google Scholar 

  20. Garfinkel D, Mamelok RD, Blaschke TF: Altered therapeutic range for quinidine after myocardial infarction an cardiac surgery. Ann Intern Med 107: 48, 1987

    PubMed  CAS  Google Scholar 

  21. Reidenberg MM: The biotransformation of drugs in renal failure. Am J Med 62: 482, 1977

    PubMed  CAS  Google Scholar 

  22. Aronoff GR, Luft FC: Antimicrobial therapy in patients with impaired renal function. Dial Transplant 8: 14, 1979

    Google Scholar 

  23. Bennett WM, Hartnett MN, Craven R, Gilbert DN, Porter GA: Gentamicin concentrations in blood, urine and renal tissue of patients with end-stage renal disease. J Lab Clin Med 90: 389, 1977

    PubMed  CAS  Google Scholar 

  24. Bennett WM, Craven R: Urinary tract infections in patients with severe renal disease: treatment with ampicillin and trimethoprim-sulfamethoxazole. JAMA 236: 946, 1976

    PubMed  CAS  Google Scholar 

  25. Elzinga L, Golper TA, Rashad AL, Carr ME, Bennett WM: Trimethoprim-sulfamethoxazole activity in cyst fluid from autosomal dominant polycystic kidneys. Kidney Int 32: 884, 1987

    PubMed  CAS  Google Scholar 

  26. Elzinga LW, Golper TA, Rashad AL, Carr ME, Bennett WM: Ciprofloxacin activity in cyst fluid from polycystic kidneys. Antimicrob Agents Chemother 32: 844, 1988

    PubMed  CAS  Google Scholar 

  27. Miller RD, Cullen DJ: Renal failure and post-operative respiratory failure: recurarization? Br J Anaesth 48: 253, 1976

    PubMed  CAS  Google Scholar 

  28. Phillips ME, Eastwood JB, Curtis JR, Gower PC, De Wardener HE: Tetracycline poisoning in renal failure, Br Med J 2(911): 149, 1974

    PubMed  CAS  Google Scholar 

  29. Al-Damluji S, Meek JH: Interference of a propranolol metabolite with serum bilirubin estimation in chronic renal failure. Br Med J 280(6229): 1414, 1980

    PubMed  CAS  Google Scholar 

  30. Molitch ME, Rodman E, Hirsch CA, Dubinsky E: Spurious serum creatinine elevations in ketoacidosis. Ann Inter Med 93:280, 1980

    CAS  Google Scholar 

  31. Baba S, Baba T, Iwanga T: Effect of acetohexamide (a sulfonylurea hypoglycemic agent) in blood plasma on creatinine assay in clinical laboratory tests. Chem Pharmacol Bull 27: 139, 1979

    CAS  Google Scholar 

  32. Maddocks J, Hann S, Hopkins M, Coles GA: The effect of methyldopa on creatinine estimation. Lancet 1(795): 157, 1973

    PubMed  CAS  Google Scholar 

  33. Ayneck ML, Berardi RR, Johnson RM: Interference of cephalosporins and cefoxitin with serum creatinine determination. Am J Hosp Pharm 38: 1348, 1981

    Google Scholar 

  34. Burgess E, Blair A, Krichman K, Cutler RE: Inhibition of renal creatinine secretion by cimetidine in humans. Renal Physiol 5: 27, 1982

    PubMed  CAS  Google Scholar 

  35. Rainer G, Rosenberg AR: Effect of co-trimoxazole on the glomerular filtration rate of healthy adults. Chemotherapy 27: 229, 1981

    Article  Google Scholar 

  36. Vincent HH, Vos MC, Akcahuseyin E, Goessens WHF, van Duyl WA, Schalekamp MADH: Drug clearance by continuous haemodiafiltration (CAVHD). Analysis of sieving coefficients and mass transfer coefficients of diffusion. Blood Purif 11: 99, 1993

    PubMed  CAS  Google Scholar 

  37. Keller F, Wilms H, Schultze G, Offerman G, Molzahn M: Effect of plasma protein binding, volume of distribution, and molecular weight on the fraction of drugs eliminated by hemodialysis. Clin Nephrol 19: 201, 1983

    PubMed  CAS  Google Scholar 

  38. Maher JF: Pharmacokinetics in patients with renal failure. Clin Nephrol 21: 39, 1984

    PubMed  CAS  Google Scholar 

  39. Dromgoole SH: The effect of hemodialysis on the binding capacity of albumin. Clinica Chim Acta 46: 269, 1973

    CAS  Google Scholar 

  40. Rutstein DD, Castelli WP, Nickerson, R: Heparin and human lipid metabolism. Lancet 1(603): 1003, 1969

    PubMed  CAS  Google Scholar 

  41. Suh B, Craig WA, England AC, Elliott RL: Effect of free fatty acids on protein binding of antimicrobial agents. J Infect Dis 143:609, 1981

    PubMed  CAS  Google Scholar 

  42. Golper TA, Saad AM: Gentamicin and phenytoin sieving through hollow-fiber polysulfone hemofilters. Kidney Int 30: 937, 1986

    PubMed  CAS  Google Scholar 

  43. Fabris A, La Greca G, Chiaramonte S et al.: Total solute extraction versus clearance in the evaluation of standard and short hemodialysis. Trans Am Soc Artif Intern Organs 34: 627, 1988

    CAS  Google Scholar 

  44. Sprenger KGB, Stephan H, Kratz W, Huber K, Franz HE: Optimizing of hemodiafiltration with modern membranes? Contrib Nephrol 46: 43, 1985

    PubMed  CAS  Google Scholar 

  45. De Bock V, Verbeelen D, Maes V, Sennesael J: Pharmacokinetics of vancomycin in patients undergoing hemodialysis and hemofiltration. Nephrol Dial Transplant 4: 635, 1989

    PubMed  Google Scholar 

  46. Matzke GR, O’Connell MB, Collins AJ, Keshaviah PR: Disposition of vancomycin during hemofiltration. Clin Pharmacol Ther 40: 425, 1986

    Article  PubMed  CAS  Google Scholar 

  47. Marbury TC, Lee CS, Perchalski RJ, Wilder BJ: Hemodialysis clearance of ethosuximide in patients with chronic renal disease. Am J Hosp Pharm 38: 1757, 1981

    PubMed  CAS  Google Scholar 

  48. Lee CS, Marbury TC, Benet LZ: Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol. J Pharmacokinet Biopharm 8: 69, 1980

    PubMed  Google Scholar 

  49. Levy G: Pharmacokinetics in renal disease. Am J Med 62: 461, 1977

    PubMed  CAS  Google Scholar 

  50. Gibson TP: Problems in designing hemodialysis drug studies. Pharmacotherapy 5: 23, 1985

    PubMed  CAS  Google Scholar 

  51. Brunner H, Mann H, Stiller S, Sieberth HG: Permeability for middle and higher molecular weight substances. Contrib Nephrol 46: 33, 1985

    PubMed  CAS  Google Scholar 

  52. Donahue PR, Ahmad S: Dialyzer permeability alteration by reuse. (Abstract) J Am Soc Nephrol 3: 363, 1992

    Google Scholar 

  53. Graeber CW, Halley SE, Lapkin RA, Kaplan AA: Protein losses with reused dialyzers. (Abstract) J Am Soc Nephrol 4: 349, 1993

    Google Scholar 

  54. Lanese DM, Alfrey PS, Molitoris BA: Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int 35: 1409, 1989

    PubMed  CAS  Google Scholar 

  55. Bastani R, Spyker DA, Minocha A, Cummings R, Westervelt FB Jr: In vivo comparison of three different hemodialysis membranes for vancomycin clearance: cuprophan, cellulose acetate, and polyacrylonitrile. Dial Transpl 17: 527, 1988

    Google Scholar 

  56. Barth RH, DeVincenzo N, Zara AC, Berlyne GM: Vancomycin pharmacokinetics in high-flux hemodialysis. (Abstract) J Am Soc Nephrol 1: 348, 1990

    Google Scholar 

  57. Agarwal R, Toto RD: Gentamicin clearance during hemodialysis: a comparison of high-efficiency cuprammonium rayon and conventional cellulose ester hemodialyzers. Am J Kidney Dis 22: 296, 1993

    PubMed  CAS  Google Scholar 

  58. Jindal K, McDougall J, Goldstein M: High flux dialyzers: impact of ultrafiltration and surface area on clearance of small and large molecular weight substances. (Abstract) Nat Kidney Found p A10, 1987

    Google Scholar 

  59. Von Albertini B, Miller JH, Gardner PW, Shinaberger JH: Performance characteristics of high flux haemodiafiltration. Proc Eur Dial Transplant Assoc 21: 447, 1984

    Google Scholar 

  60. Surian M, Malberti F, Corradi B et al.: Adequacy of haemodiafiltration. Nephrol Dial Transplant 4: 32, 1989

    PubMed  CAS  Google Scholar 

  61. Rumpf KW, Rieger J, Doht B, Ansorg R, Scheler F: Drug elimination by hemofiltration. J Dialysis 1: 677, 1977

    CAS  Google Scholar 

  62. Ernest D, Cutler DJ: Gentamicin clearance during continuous arteriovenous hemodiafiltration. Crit Care Med 20: 586, 1992

    PubMed  CAS  Google Scholar 

  63. Rumpf KW, Rieger J, Ansorg R et al.: Binding of antibiotics by dialysis membranes and its clinical relevance. Proc Eur Dial Transpl Assoc 14: 607, 1978

    Google Scholar 

  64. Kraft D, Lode H: Elimination of ampicillin and gentamicin by hemofiltration. Klin Wochenschr 57: 195, 1979

    PubMed  CAS  Google Scholar 

  65. Kronfol NO, Lau AH, Barakat MM: Aminoglycoside binding to polyacrylonitrile hemofilter membranes during continuous hemofiltration. Trans Am Soc Artif Intern Organs 33: 300, 1987

    CAS  Google Scholar 

  66. Kronfol N, Lau AH, Colon-Rivera J, Libertin CL; Effect of CAVH membrane types on drug sieving coefficients and clearances. Trans Am Soc Artif Intern Organs 32: 85, 1986

    CAS  Google Scholar 

  67. Lau AH, Kronfol NO, Jaber N, Libertin CL: Determinants of drug removal by continuous arteriovenous hemofiltration. (Abstract) Drug Intell Clin Pharm 20: 467, 1986

    Google Scholar 

  68. Kronfol N, Lau A, Jaber N, Libertin CL: Effect of membrane properties on drug clearances by CAVH. (Abstract) Nat Kidney Found A10, 1986

    Google Scholar 

  69. Henderson LW: Hemodialysis: rationale and physical principles, in The Kidney, 1st Edition, edited by Brenner BM, Rector FC, Philadelphia, WB Sanders Company, 1976, p 1643

    Google Scholar 

  70. Husted FC, Nolph KD, Vitale FC, Maher JF: Detrimental effects of ultrafiltration on diffusion in coils. J Lab Clin Med 87: 435, 1976

    PubMed  CAS  Google Scholar 

  71. Nolph KD, New DL: Effects of ultrafiltration on solute clearances in hollow fiber artificial kidneys. J Lab Clin Med 88:593, 1976

    PubMed  CAS  Google Scholar 

  72. Nolph KD, Hopkins C, Van Stone J: Effects of ultrafiltration on solute clearances in parallel plate dialyzars. Clin Nephrol 8: 453, 1977

    PubMed  CAS  Google Scholar 

  73. Henderson LW, Silverstein ME, Ford CA, Lysaght MJ: Clinical response to maintenance hemodiafiltration. Kidney Int (Suppl 2): S58, 1975

    Google Scholar 

  74. Hamilton R, Ford C, Colton C, Cross R, Steinmuller S, Henderson L: Blood cleansing by diafiltration in uremic dog and man. Trans Am Soc Artif Intern Organs 17: 259, 1971

    PubMed  CAS  Google Scholar 

  75. Henderson LW, Ford C, Colton CK, Bluemle LW, Bixler HJ: Uremic blood cleansing by diafiltration using hollow-fiber ultrafilter. Trans Am Soc Artif Intern Organs 16: 107. 1970

    PubMed  CAS  Google Scholar 

  76. Jaffrin MY, Ding L, Laurent JM: Simultaneous convective and diffusive mass transfers in a hemodialyzer. J Biomech Eng 112: 212, 1990

    PubMed  CAS  Google Scholar 

  77. Vincent HH, van Ittersum FJ, Akcahuseyin E, Vos MC, Van Duyl WA, Schalekamp MA: Solute transport in continuous arteriovenous hemodiafiltration: a new mathematical model applied to clinical data. Blood Purif 8: 9, 1990

    Google Scholar 

  78. Torras J, Cao C, Rivas MC, Cano M, Fernandez E, Montoliu J: Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile. Clin Nephrol 36: 35, 1991

    PubMed  CAS  Google Scholar 

  79. Colton CK, Henderson LW, Ford CA, Lysaght MJ. Kinetics of hemodiafiltration. I. In vitro transport characteristics of a hollow fiber blood ultrafilter. J Lab Clin Med 85: 355, 1975

    PubMed  CAS  Google Scholar 

  80. Golper TA, Wedel SK, Kaplan AA, Saad AM, Donta ST. Paganini EP: Drug removal during CAVH: theory and clinical observations. Intern J Artif Organs 8: 307, 1985

    CAS  Google Scholar 

  81. Ronco C, Brendolan A, Borin D et al.: Permeability characteristics of polysulfonic membranes in CAVH, in Continuous Arteriovenous Hemofiltration (CAVH), edited by Sieberth HG, Mann H, Basel, Karger, 1985, p 59

    Google Scholar 

  82. Frigon RP, Leypoldt JK, Alford MF, Uyeji S, Henderson LW: Hemofilter solute sieving is not governed by dynamically polarized protein. Trans Am Soc Artif Intern Organs 30: 486, 1984

    PubMed  CAS  Google Scholar 

  83. Lysaght MJ: An experimental model for the ultrafiltration of sodium ion from blood or plasma. Blood Purif 1: 25, 1983

    CAS  Google Scholar 

  84. Leypoldt JK, Frigon RP, Henderson LW: Macromolecular charge affects hemofilter solute sieving. Trans Am Soc Artif Intern Organs 32: 384, 1986

    CAS  Google Scholar 

  85. Kaplan AA, Longnecker RE, Folkert VW: Continuous arteriovenous hemofiltration — a report of 6 months’ experience. Ann Intern Med 100: 358, 1984

    PubMed  CAS  Google Scholar 

  86. Paganini EP, Flague J, Whitman G, Nakamoto S: Amino acid balance in patients with oliguric renal failure undergoing slow continuous ultrafiltration (SCUF). Trans Am Soc Artif Intern Organs 28: 615, 1982

    PubMed  CAS  Google Scholar 

  87. Golper TA, Vincent HH, Kroh U: Drug use in critically ill patients with acute renal failure, in Acute Renal Failure in the Critically III, edited by Bellomo R, Ronco C, Heidelberg, Springer-Verlag, 1995. In press

    Google Scholar 

  88. Kroh U, Hofmann W, Dehne M, el Abed K, Lennartz H: Dosisanpassung von pharmaka während kontinuierlicher hämofiltration. Anaesthesist 38: 225, 1989

    PubMed  CAS  Google Scholar 

  89. Leypoldt JK, Frigon RP, Henderson LW: Dextran sieving coefficients of hemofilter membranes. Trans Am Soc Artif Intern Organs 29: 678, 1983

    PubMed  CAS  Google Scholar 

  90. Dodd NJ, O’Donovan RM, Bennett-Jones DN et al.: Arteriovenous hemofiltration: a recent advance in the management of renal failure. Br Med J 287: 1008, 1983

    CAS  Google Scholar 

  91. Bennett WM, Aronoff GR, Golper TA, Morrison G, Brater DC, Singer I: Drug Prescribing in Renal Failure: Dosing Guidelines for Adults, 3rd Edition. Philadelphia, American College of Physicians, 1994

    Google Scholar 

  92. Keller E, Reetze P, Schollmeyer P: Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clin Pharmacokinet 18: 104, 1990

    PubMed  CAS  Google Scholar 

  93. Golper TA: Drugs and peritoneal dialysis. Dial Transplant 8:41, 1979

    Google Scholar 

  94. Lasrich M, Maher JM, Hirszel P, Maher JF: Correlation of peritoneal transport rates with molecular weight: a method for predicting clearances. ASAIO J 2: 107, 1979

    Google Scholar 

  95. Nolph KD, Popovich RP, Ghods AS, Twardowski Z: Determinants of low clearances of small solutes during peritoneal dialysis. Kidney Int 13: 117, 1978

    PubMed  CAS  Google Scholar 

  96. Robson M, Oreopoulos DG, Izatt S, Olivie R, Rapaport R, de Veber GA: Influence of exchange volume and dialysate flow rate on solute clearance in peritoneal dialysis. Kidney Int 14: 486, 1978

    PubMed  CAS  Google Scholar 

  97. Zelman A, Gisser D, Whitlam PJ, Parsons RH, Shuyler R: Augmentation of peritoneal dialysis efficiency with programmed hyper/hypoosmotic dialysates. Trans Am Soc Artif Intern Organs 23: 203, 1977

    PubMed  CAS  Google Scholar 

  98. Rubin J, Adair C, Barnes T, Bower J: Dialysate flow rate and peritoneal clearance. Am J Kidney Dis 4: 260, 1984

    PubMed  CAS  Google Scholar 

  99. Gross M, McDonald HP: Effect of dialysate temperature and flow rate on peritoneal clearance. JAMA 202: 363, 1967

    PubMed  CAS  Google Scholar 

  100. Indraprasit S, Namwongprom A, Sooksriwongse C, Buri PS: Effect of dialysate temperature on peritoneal clearances. Nephron 34: 45, 1983

    PubMed  CAS  Google Scholar 

  101. Manuel MA, Paton TW, Cornish WR: Drugs and peritoneal dialysis. Perit Dial Bull 3: 117, 1983

    Google Scholar 

  102. Janknegt R, Koks CH: Pharmacologic aspects during continuous ambulatory peritoneal dialysis: a literature review. Pharmaceutisch Weekblad 6: 229, 1984

    CAS  Google Scholar 

  103. Paton TW, Cornish WR, Manuel MA, Hardy BG: Drug therapy in patients undergoing peritoneal dialysis: clinical pharmacokinetic considerations. Clin Pharmacokinet 10: 404, 1985

    PubMed  CAS  Google Scholar 

  104. Smithivas T, Hyams PJ, Matalon R, Simberkoff MS, Rahal JJ Jr: The use of gentamicin in peritoneal dialysis. I. Pharmacologic results. J Infect Dis 124(Suppl): S77, 1971

    Google Scholar 

  105. Singlas E, Colin JN, Rottenbourg J et al.: Pharmacokinetics of sulfamethoxazole-trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis. Eur J Clin Pharmacol 21: 409, 1982

    PubMed  CAS  Google Scholar 

  106. Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC: Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 33: 66, 1983

    Article  PubMed  CAS  Google Scholar 

  107. Roscoe JM: Practices of insulin administration in CAPD. Perit Dial Bull 2(Suppl 2): S27, 1982

    Google Scholar 

  108. Furman KI, Gomperts ED, Hockley J: Activity of intraperitoneal heparin during peritoneal dialysis. Clin Nephrol 9: 15, 1978

    PubMed  CAS  Google Scholar 

  109. Golper TA, Bennett WM, Jones SR: Peritonitis associated with chronic peritoneal dialysis: a diagnostic and therapeutic approach. Dial Transplant 7: 282, 1978

    Google Scholar 

  110. Millikin SP, Matzke GR, Keane WF: Antimicrobial treatment of peritonitis associated with continuous ambulator peritoneal dialysis. Perit Dial Int 11: 252, 1991

    PubMed  CAS  Google Scholar 

  111. Sewell DL, Golper TA, Brown SD, Nelson E, Knower M, Kimbrough RC: Stability of single and combination antimicrobial agents in various peritoneal dialysates in the presence of insulin and heparin. Am J Kidney Dis 3: 209, 1983

    PubMed  CAS  Google Scholar 

  112. Blaser J, Rüttimann S, Bhend H, Luthy R: Increase of amikacin half-life during therapy in patients with renal insufficiency. Antimicrob Agents Chemother 23: 888, 1983

    PubMed  CAS  Google Scholar 

  113. Lanao JM, Dominguez-Gil A, Tabemero JM, Sanchez Tomero JA: Pharmacokinetics of amikacin (BB-K8) in patients undergoing hemodialysis. Int J Clin Pharmacol Biopharm 17: 357, 1979

    PubMed  CAS  Google Scholar 

  114. Smeltzer BD, Schwartzman MS, Bertino JS: Amikacin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 32: 236, 1988

    PubMed  CAS  Google Scholar 

  115. Goetz DR, Pancorbo S, Hoag S, Bloom P: Prediction of serum gentamicin concentrations in patients undergoing hemodialysis. Am J Hosp Pharm 37: 1077, 1980

    PubMed  CAS  Google Scholar 

  116. Gyselynck AM, Forrey A, Cutler R: Pharmacokinetics of gentamicin: distribution and plasma and renal clearance. J Infect Dis 124(Suppl): S70, 1971

    Google Scholar 

  117. Zarowitz BJ, Anandan JV, Dumler F et al.: Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients. J Clin Pharmacol 26: 686, 1986

    PubMed  CAS  Google Scholar 

  118. Healy JK, Drum PJ, Elliott AJ: Kanamycin dosage in renal failure. Aust N Z J Med 3: 474, 1973

    PubMed  CAS  Google Scholar 

  119. Campoli-Richards DM, Chaplin S, Sayce RH, Goa KL: Netilmicin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 38: 703, 1989

    PubMed  CAS  Google Scholar 

  120. Herrero A, Rius Alarcó F, García Díez JM, Mahiques E, Domingo JV: Pharmacokinetics of netilmicin in renal insufficiency and hemodialysis. Int J Clin Pharmacol Ther Toxicol 26: 84, 1988

    PubMed  CAS  Google Scholar 

  121. Pechére JC, Dugal R, Pechére MM: Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis. Clin Pharmacokinet 3: 395, 1978

    PubMed  Google Scholar 

  122. Seyffart G (ed): Drug Dosage in Renal Insufficiency, Dordrecht, The Netherlands, Kluwer Academic Publishers, 1991

    Google Scholar 

  123. Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS: Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs 12: 166, 1976

    PubMed  CAS  Google Scholar 

  124. Pechere JC, Dugal R: Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renal-impaired and hemodialyzed patients. J Infect Dis 134(Suppl): S118, 1976

    CAS  Google Scholar 

  125. Wise R: The pharmacokinetics of the oral cephalosporins — a review. J Antimicrob Chemother 26(Suppl E): 13, 1990

    PubMed  CAS  Google Scholar 

  126. Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E: Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis. J Antimicrob Chemother 5: 465, 1979

    PubMed  CAS  Google Scholar 

  127. Leroy A, Humbert G, Godin M: Pharmacokinetics of cefadroxil in patients with impaired renal function. J Antimicrob Chemother 10(Suppl B): 39, 1982

    PubMed  Google Scholar 

  128. Bliss M, Mayersohn M, Arnold T, Logan J, Michael UF, Jones W: Disposition kinetics of cefamandole during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 29: 649, 1986

    PubMed  CAS  Google Scholar 

  129. Brogard JM, Kopferschmitt J, Spach MO, Grudet O, Lavillaureix J: Cefamandole pharmacokinetics and dosage adjustments in relation to renal function. J Clin Pharmacol 19: 366, 1979

    PubMed  CAS  Google Scholar 

  130. Bergan T, Brodwall EK, Ørjavik Ø: Pharmacokinetics of cefazolin in patients with normal and impaired renal function. J Antimicrob Chemother 3: 453, 1977

    Google Scholar 

  131. Guay DRP, Meatherall RC, Harding GK, Brown GR: Pharmacokinetics of cefixime (CL 284,635; FK027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother 30: 458, 1986

    Google Scholar 

  132. Campoli-Richards DM, Todd PA: Cefmenoxime. A review of its antibacterial activity pharmacokinetic properties and therapeutic use. Drugs 34: 188, 1987

    PubMed  CAS  Google Scholar 

  133. Evers J, Borner K, Koeppe P: Elimination of cefmenoxime during continuous haemofiltration. Eur J Clin Pharmacol 44(Suppl 1): S31, 1993

    Google Scholar 

  134. Konishi K: Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis. Antimicrob Agents Chemother 30: 901, 1986

    PubMed  CAS  Google Scholar 

  135. Halstenson CE, Guay DR, Opsahl JA et al.: Disposition of cefmetazole in healthy volunteers and patients with impaired renal function. Antimicrob Agents Chemother 34:519, 1990

    PubMed  CAS  Google Scholar 

  136. Schentag JJ: Cefmetazole sodium: pharmacology, pharmacokinetics, and clinical trials. Pharmacotherapy 11:2, 1991

    PubMed  CAS  Google Scholar 

  137. Blair AD, Maxwell BM, Forland SC, Jacob L, Cutler RE: Cefonicid kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther 35: 798, 1984

    Article  PubMed  CAS  Google Scholar 

  138. Saltiel E, Brogden RN: Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 32: 222, 1986

    PubMed  CAS  Google Scholar 

  139. Greenfield RA, Gerber AU, Craig WA: Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function. Rev Infect Dis 5(Suppl): S 127, 1983

    Google Scholar 

  140. Hodler JE, Galeazzi RL, Frey B, Rudhardt M, Seiler AJ: Pharmacokinetics of cefoperazone in patients undergoing chronic ambulatory peritoneal dialysis: clinical and pathophysiological implications. Eur J Clin Pharmacol 26: 609, 1984

    PubMed  CAS  Google Scholar 

  141. Campoli-Richards DM, Lackner TE, Monk JP: Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 34: 411, 1987

    PubMed  CAS  Google Scholar 

  142. Hess JR, Berman SJ, Boughton WH et al.: Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis. Antimicrob Agents Chemother 17: 251, 1980

    PubMed  CAS  Google Scholar 

  143. Matzke GR, Abraham PA, Halstenson CE, Keane WF: Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther 38: 31, 1985

    Article  PubMed  CAS  Google Scholar 

  144. Todd PA, Brogden RN: Cefotaxime. An update of its pharmacology and therapeutic use. Drugs 40: 608, 1990

    PubMed  CAS  Google Scholar 

  145. Ohkawa M, Hirano S, Tokunaga S: Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function. Antimicrob Agents Chemother 23: 31, 1983

    PubMed  CAS  Google Scholar 

  146. Ward A, Richards DM: Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 30: 382, 1985

    PubMed  CAS  Google Scholar 

  147. Greaves WL, Kreeft JH, Ogilvie RI, Richards GK: Cefoxitin disposition during peritoneal dialysis. Antimicrob Agents Chemother 19: 253, 1981

    PubMed  CAS  Google Scholar 

  148. Humbert G, Fillastre JP, Leroy A, Godin M, Van Winzum C: Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency. Rev Infect Dis 1: 118, 1979

    PubMed  CAS  Google Scholar 

  149. Nikolaidis P, Tourkantonis A: Effect of hemodialysis on ceftazidime pharmacokinetics. Clin Nephrol 24: 142, 1985

    PubMed  CAS  Google Scholar 

  150. Richards DM, Brogden RN: Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 29: 105, 1985

    PubMed  CAS  Google Scholar 

  151. Tourkantonis A, Nicolaidis P: Pharmacokinetics of ceftazidime in patients undergoing peritoneal dialysis. J Antimicrob Chemother 12(Suppl A): 263, 1983

    PubMed  Google Scholar 

  152. Welage LS, Schultz RW, Schentag JJ: Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother 25: 201, 1984

    PubMed  CAS  Google Scholar 

  153. Burgess ED, Blair AD: Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 24: 237, 1983

    PubMed  CAS  Google Scholar 

  154. Gross ML, Somani P, Ribner BS, Roeader R, Freimer EH, Higgins JT Jr: Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 34: 673, 1983

    Article  PubMed  CAS  Google Scholar 

  155. Kowalsky SF, Echols RM, Venezia AR, Andrews EA: Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function. Antimicrob Agents Chemother 24: 151, 1983

    PubMed  CAS  Google Scholar 

  156. Richards DM, Heel RC: Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 29: 281, 1985

    PubMed  CAS  Google Scholar 

  157. Patel IH, Sugihara JG, Weinfeld RE, Wong EG, Siemsen AW, Berman SJ: Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother 25: 438, 1984

    PubMed  CAS  Google Scholar 

  158. Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ: Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis. Antimicrob Agent Chemother 25: 83, 1984

    CAS  Google Scholar 

  159. Yuk JH, Nightingale CH, Quintiliani R: Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinet 17: 223, 1989

    PubMed  CAS  Google Scholar 

  160. Höffler D, Koeppe P, Schleith A: Pharmacokinetics of cefuroxime-axetil in patients undergoing haemodialysis therapy. Acta Therapeutica 17: 107, 1991

    Google Scholar 

  161. Konishi K, Suzuki H, Hayashi M, Saruta T: Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function. J Antimicrob Chemother 31: 413, 1993

    PubMed  CAS  Google Scholar 

  162. Weiss LG, Cars O, Danielson BG, Grahnen A, Wikstrom B: Pharmacokinetics of intravenous cefuroxime during intermittent and continuous arteriovenous hemofiltration. Clin Nephrol 30: 282, 1988

    PubMed  CAS  Google Scholar 

  163. Bailey RR, Gower PE, Dash CH: The effects of impairment of renal function and haemodialysis on serum and urine levels of cephalexin. Postgrad Med J 46(Suppl): 60, 1970

    Google Scholar 

  164. Venuto RC, Plaut M: Cephalothin handling in patients undergoing hemodialysis. Antimicrob Agents Chemother 10: 50, 1970

    PubMed  CAS  Google Scholar 

  165. McCloskey RV, Terry EE, McCracken AW, Sweeney MJ, Forland MF: Effect of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium. Antimicrob Agents Chemother 1: 90, 1972

    PubMed  CAS  Google Scholar 

  166. Solomon AE, Briggs JD: The administration of cephradine to patients in renal failure. Br J Clin Pharmacol 2: 443, 1975

    PubMed  CAS  Google Scholar 

  167. Bolton WK, Scheld WM, Spyker DA, Overby TL, Sande MA: Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction. Antimicrob Agents Chemother 18:933, 1980

    PubMed  CAS  Google Scholar 

  168. Carmine AA, Brogden RN, Heel RC, Romankiewicz JA, Speight TM, Avery GS: Moxalactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. drugs 26: 279, 1983

    PubMed  CAS  Google Scholar 

  169. Srinivasan S, Neu HC: Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis. Antimicrob Agents Chemother 20: 398, 1981

    PubMed  CAS  Google Scholar 

  170. Cooper MA, Nye K, Andrews JM, Wise R: The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin. J Antimicrob Chemother 26: 533, 1990

    PubMed  CAS  Google Scholar 

  171. Foulds G, Shephard RM, Johnson RB: The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25(Suppl A): 73, 1990

    PubMed  CAS  Google Scholar 

  172. Peters DH, Clissold SP: Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 44: 117, 1992

    PubMed  CAS  Google Scholar 

  173. Disse B, Gundert-Remy U, Weber E, Andrassy K, Sietzen W, Lang A: Pharmacokinetics of erythromycin in patients with different degrees of renal impairment. Int J Clin Pharmacol Ther Toxicol 24: 460, 1986

    PubMed  CAS  Google Scholar 

  174. Kanfer A, Stamatakis G, Torlotin C, Fredj G, Kenouch S, Mery JP: Changes in erythromycin pharmacokinetic induced by renal failure. Clin Nephrol 27: 247, 1987

    Google Scholar 

  175. Francke EL, Appel GB, Neu HC: Kinetics of intravenous amoxicillin in patients on long-term dialysis. Clin Pharmacol Ther 26: 3, 1979

    Google Scholar 

  176. Humbert G, Spyker DA, Fillastre JP, Leroy A: Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function. Antimicrob Agents Chemother 15: 28, 1979

    PubMed  CAS  Google Scholar 

  177. Todd PA, Benfield P: Amoxicillin/clavulanic acid: an update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 39: 264, 1990

    PubMed  CAS  Google Scholar 

  178. Blum RA, Kohli RK, Harrison NJ, Schentag JJ: Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother 33: 1470, 1989

    PubMed  CAS  Google Scholar 

  179. Leroy A, Humbert G, Godin M, Fillastre JP: Pharmacokinetics of azlocillin in subjects with normal and impaired renal function. Antimicrob Agents Chemother 17: 344, 1980

    PubMed  CAS  Google Scholar 

  180. Whelton A, Stout RL, Delgado FA: Azlocillin kinetics during extracorporeal haemodialysis and peritoneal dialysis. J Antimicrob Chemother 11(Suppl B): 89, 1983

    PubMed  Google Scholar 

  181. Aronoff GR, Sloan RS, Luft FC, Nelson RL, Maxwell DR, Kleit SA: Mezlocillin pharmacokinetics in renal impairment. Clin Pharmacol Ther 28: 523, 1980

    Article  PubMed  CAS  Google Scholar 

  182. Kampf D, Schurig R, Weihermüller K, Forester D: Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin. Antimicrob Agents Chemother 18: 81, 1980

    PubMed  CAS  Google Scholar 

  183. Baron DN, Hamilton-Miller JM, Brumfitt W: Sodium content of injectable β-Lactam antibiotics. Lancet i(8386): 1113, 1984

    Google Scholar 

  184. Holmes B, Richards DM, Brogden RN, Heel RC: Piperacillin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 28: 375, 1984

    PubMed  CAS  Google Scholar 

  185. De Schepper PJ, Tjandramage RB, Mullie A et al.: Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure. J Antimicrob Chemother 9Suppl B): 1982

    Google Scholar 

  186. Welling PG, Craig WA, Bundtzen RW, Kwok FW, Gerber AU, Madsen PO: Pharmacokinetics of piperacillin in subjects with various degrees of renal function. Antimicrob Agents Chemother 23: 881, 1983

    PubMed  CAS  Google Scholar 

  187. Parry MF, Neu HC: Pharmacokinetics of ticarcillin in patients with abnormal renal function. J Infect Dis 133: 46, 1976

    PubMed  CAS  Google Scholar 

  188. Vance-Bryan K, Guay DR, Rotschafer JC: Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 19: 434, 1990

    PubMed  CAS  Google Scholar 

  189. Davies SP, Azadian BS, Kox WJ, Brown EA: Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. Nephrol Dial Transplant 7: 848, 1992

    PubMed  CAS  Google Scholar 

  190. Kowalsky SF, Echols M, Schwartz MT, Baile GR, McCCormick E: Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. Clin Nephrol 39: 53, 1993

    PubMed  CAS  Google Scholar 

  191. Neuman M: Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet 14: 96, 1988

    PubMed  CAS  Google Scholar 

  192. Henwood JM, Monk JP: Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 36: 32, 1988

    PubMed  CAS  Google Scholar 

  193. Nix DE, Schultz RW, Frost RW et al.: The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin. J Antimicrob Chemother 21(Suppl B): 87, 1988

    PubMed  CAS  Google Scholar 

  194. Weidekamm E: Pharmacokinetics of fleroxacin in renal impairment. Am J Med 94: 70S, 1993

    Google Scholar 

  195. Holmes B, Brogden RN, Richards DM: Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 30: 482, 1985

    PubMed  CAS  Google Scholar 

  196. Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S: Ofloxacin pharmacokinetics in chronic renal failure and dialysis. Clin Pharmacokinet 21: 357, 1991

    PubMed  CAS  Google Scholar 

  197. Saivin S, Houin G: Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 15: 355, 1988

    PubMed  CAS  Google Scholar 

  198. Siegel D: Tetracyclines: new look at old antibiotic. I. Clinical pharmacology, mechanism of action, and untoward effects. N Y State J Med 78: 950, 1978

    PubMed  CAS  Google Scholar 

  199. Fillastre JP, Leroy A, Baudoin C et al.: Pharmacokinetics of aztreonam in patients with chronic renal failure. Clin Pharmacokinet 10: 91, 1985

    PubMed  CAS  Google Scholar 

  200. Gerig JS, Bolton ND, Swabb EA, Scheid WM, Bolton WK: Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics. Kidney Int 26: 308, 1984

    PubMed  CAS  Google Scholar 

  201. Ambrose PJ: Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin Pharmacokinet 9: 222, 1984

    PubMed  CAS  Google Scholar 

  202. Buckley MM, Brogden RN, Barradell LB, Goa KL: Imipenem/Cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 44: 408, 1992

    PubMed  CAS  Google Scholar 

  203. Gibson TP, Devetriades JL, Bland JA: Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. Am J Med 78(Suppl 6A): 54, 1985

    PubMed  CAS  Google Scholar 

  204. Konishi K, Suzuki H, Saruta T et al.: Removal of imipenem and cilastatin by hemodialysis in patients with end stage renal failure. Antimicrob Agents Chemother 35: 1616, 1991

    PubMed  CAS  Google Scholar 

  205. Vos MC, Vincent HH, Yzerman EP: Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD). Intensive Care Med 18:282, 1992

    PubMed  CAS  Google Scholar 

  206. Roberts AP, Eastwood JB, Gower PE, Fenton C, Curtis J: Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects. Eur J Clin Pharmacol 14: 435, 1978

    PubMed  CAS  Google Scholar 

  207. Guay DR, Meatherall RC, Baxter H, Jacyk WR, Penner B: Pharmacokinetics of metronidazole in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 25: 306, 1984

    PubMed  CAS  Google Scholar 

  208. Kreeft JH, Ogilvie RI, Dufresne LR: Metronidazole kinetics in dialysis patients. Surgery 93: 149, 1983

    PubMed  CAS  Google Scholar 

  209. Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danzinger LH: Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 23: 328, 1992

    Article  PubMed  CAS  Google Scholar 

  210. Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S: Pharmacokinetics of sulfisoxazole in renal transplant patients. Antimicrob Agents Chemother 28: 535, 1985

    PubMed  CAS  Google Scholar 

  211. Bonati M, Traina GL, Villa G et al.: Teicoplanin pharmacokinetics in patients with chronic renal failure. Clin Pharmacokinet 12: 292, 1987

    PubMed  CAS  Google Scholar 

  212. Campoli-Richards DM, Brogden RN, Faulds D: Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 40: 449, 1990

    PubMed  CAS  Google Scholar 

  213. Paap CM, Nahata MC: Clinical use of trimethoprim/sulfamethoxazole during renal dysfunction. DICP, Ann Pharmacother 23: 646, 1989

    CAS  Google Scholar 

  214. Moellering RC, Krogstad DJ, Greenblatt DJ: Vancomycin therapy in patients with impaired renal function; a nomogram for dosage. Ann Intern Med 94: 343, 1981

    PubMed  Google Scholar 

  215. Nielsen HE, Sorensen I, Hansen HE: Peritoneal transport of vancomycin during peritoneal dialysis. Nephron 24: 274, 1979

    PubMed  CAS  Google Scholar 

  216. Daneshmend TK, Warnock DW: Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 8: 17, 1983

    PubMed  CAS  Google Scholar 

  217. Lyman CA, Walsh TJ: Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44: 9, 1992

    PubMed  CAS  Google Scholar 

  218. Craven PC, Ludden TM, Drutz DJ, Rogers W, Haegele KA, Skrdlant HB: Excretion pathways of amphotericin B. J Infect Dis 140: 329, 1979

    PubMed  CAS  Google Scholar 

  219. Morgan DJ, Ching MS, Raymond K et al.: Elimination of amphotericin B in impaired renal function. Clin Pharmacol Ther 34: 248, 1983

    Article  PubMed  CAS  Google Scholar 

  220. Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ: Liposomal and lipid formulations amphotericin B. Clin Pharmacokinet 23: 279, 1992

    PubMed  CAS  Google Scholar 

  221. Cleary JD, Taylor JW, Chapman SW: Imidazoles and triazoles in antifungal therapy. Ann Pharmacother 26: 502, 1992

    PubMed  CAS  Google Scholar 

  222. Bailey EM, Krakovsky DJ, Rybak MJ: The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy 10: 146, 1990

    PubMed  CAS  Google Scholar 

  223. Toon S, Ross CE, Gokal R, Rowand M: An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol 29: 221, 1990

    PubMed  CAS  Google Scholar 

  224. Oono S, Tabei K, Tetsuka T, Asano Y: The pharmacokinetics of fluconazole during haemodialysis in uraemic patients. Eur J Clin Pharmacol 42: 667, 1992

    PubMed  CAS  Google Scholar 

  225. Debruyne D, Ryckelynck JP: Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 24: 10, 1993

    Article  PubMed  CAS  Google Scholar 

  226. Bennet JE: Flucytosine. Ann Intern Med 86: 319, 1977

    PubMed  CAS  Google Scholar 

  227. Cutler RE, Blair AD, Kelly MR: Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther 24: 333, 1978

    PubMed  CAS  Google Scholar 

  228. Eisenberg ES: Intraperitoneal flucytosine in the management of fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 11: 465, 1988

    PubMed  CAS  Google Scholar 

  229. Boelaert J, Schurgers M, Matthys E et al.: Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrob Agents Chemother 32: 1595, 1988

    PubMed  CAS  Google Scholar 

  230. Grant SM, Clissold SP: Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37: 310, 1989

    PubMed  CAS  Google Scholar 

  231. Daneshmend TK, Warnock DW: Clinical pharmacokinetics of ketoconazole. Clin Pharmacokin 14: 13, 1988

    CAS  Google Scholar 

  232. Lewi PJ, Boelaert J, Daneels R et al.: Pharmacokinetic profile of intravenous miconazole in man. Eur J Clin Pharmacol 10: 49, 1976

    CAS  Google Scholar 

  233. White NJ: Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 10: 187, 1985

    PubMed  CAS  Google Scholar 

  234. White NJ: Antimalarial pharmacokinetics and treatment regimens. BrJ Clin Pharmacol 34: 1, 1992

    CAS  Google Scholar 

  235. Edwards G, Breckenridge AM: Clinical pharmacokinetics of anthelmintic drugs. Clin Pharmacokinet 15: 67, 1988

    PubMed  CAS  Google Scholar 

  236. Keystone JS, Murdoch JK: Mebendazole. Ann Intern Med 91:582, 1979

    PubMed  CAS  Google Scholar 

  237. Palmer KJ, Holliday SM, Brogden RN: Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 45: 430, 1993

    PubMed  CAS  Google Scholar 

  238. Goa KL, Compoli-Richards DM: Pentamidine Isethionate. A review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia. Drugs 33: 242, 1987

    PubMed  CAS  Google Scholar 

  239. Conte JE Jr: Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. J Infect Dis 163: 169, 1991

    PubMed  Google Scholar 

  240. King CH, Mahmoud AA: Drugs five years later: praziquantel. Ann Intern Med 110: 290, 1989

    PubMed  CAS  Google Scholar 

  241. Lehmann CR, Garrett LE, Winn RE et al.: Capreomycin kinetics in renal impairment and clearance by hemodialysis. Ann Rev Respir Dis 138: 1312, 1988

    CAS  Google Scholar 

  242. Varughese A, Brater DC, Benet LZ, Lee CS: Ethambutol kinetics in patients with impaired renal function. Am Rev Respir Dis 134: 34, 1986

    PubMed  CAS  Google Scholar 

  243. Weber WW, Hein DW: Clinical pharmacokinetics of iso-niazid. Clin Pharmacokinet 4: 401, 1979

    PubMed  CAS  Google Scholar 

  244. Lacroix C, Hermelin A, Guiberteau R et al.: Haemodialysis of pyrazinamide in uraemic patients. Eur J Clin Pharmacol 37: 309, 1989

    PubMed  CAS  Google Scholar 

  245. Stamatikis G, Montes C, Trouvin JH et al.: Pyrazinamide and pyrazinoic acid pharmacokinetics inpatients with chronic renal failure. Clin Nephrol 30: 230, 1988

    Google Scholar 

  246. Acocella G: Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 3: 108, 1978

    PubMed  CAS  Google Scholar 

  247. Burgess ED, Gill MJ: Intraperitoneal administration of acyclovir in patients receiving continuous ambulatory peritoneal dialysis. J Clin Pharmacol 30: 997, 1990

    PubMed  CAS  Google Scholar 

  248. Laskin OL, Longstreth JA, Whelton A et al.: Acyclovir kinetics in end-stage renal disease. Clin Pharmacol Ther 31:594: 1982

    Article  PubMed  CAS  Google Scholar 

  249. O’Brien JJ, Campoli-Richards DM: Acyclovir: an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 37: 233, 1989

    PubMed  CAS  Google Scholar 

  250. Aoki FY, Sitar DS: Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 14: 35, 1988

    PubMed  CAS  Google Scholar 

  251. Horadam VW, Sharp JG, Smilack JD, McAnalley BH, Garriott JC, Stephens MK: Pharmacokinetics amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 94: 454, 1981

    PubMed  CAS  Google Scholar 

  252. Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC: Amantadine hydrochloride pharmacokinetics patients with impaired renal function. Clin Nephrol 17: 19, 1982

    PubMed  CAS  Google Scholar 

  253. Morse GD, Shelton MJ, O’Donnell AM: Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet 24: 101, 1993

    PubMed  CAS  Google Scholar 

  254. Faulds D, Brogden RN: Didanosine: a review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 44: 94, 1992

    PubMed  CAS  Google Scholar 

  255. Chrisp P, Clissold SP: Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41: 104, 1991

    PubMed  CAS  Google Scholar 

  256. Faulds D, Heel RC: Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 39: 597, 1990

    PubMed  CAS  Google Scholar 

  257. Kramer TH, Gaar GG, Ray CG, Minnich L, Copeland JG, Connor JD: Hemodialysis clearance of intravenously administered ribavirin. Antimicrob Agents Chemother 34: 489, 1990

    PubMed  CAS  Google Scholar 

  258. Aronoff GR, Szwed JJ, Nelson RL, Marcus RL, Kleit SA: Hypoxanthine-arabinoside pharmacokinetics after adenine arabinoside administration to a patient with renal failure. Antimicrob Agents Chemother 18: 212, 1980

    PubMed  CAS  Google Scholar 

  259. Collins JM, Unadkat JD: Clinical pharmacokinetics of zidovudine. An overview of current data. Clin Pharmacokinet 17: 1, 1989

    PubMed  CAS  Google Scholar 

  260. Gallicano KD, Tobe S, Saha J et al.: Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). J Acquir Immune Defic Syndr 5: 242, 1992

    PubMed  CAS  Google Scholar 

  261. Garraffo R, Cassuto-Viguier E, Barillon J, Changlet L, Lapalus P, Duplay H: Influence of hemodialysis on zidovudine (AZT) and its glucuronide (GAZT) pharmacokinetics: two case reports. Int J Clin Pharmacol Ther Toxicol 27: 535, 1989

    PubMed  CAS  Google Scholar 

  262. Gleason JR, Brier ME: Zidovudine in renal failure. Semin Dial 3: 101, 1990

    Google Scholar 

  263. Chan GL, Matzke GR: Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Drug Intell Clin Pharm 21: 773, 1987

    PubMed  CAS  Google Scholar 

  264. Horton MW, Byerly WG: Opioid analgesics. Semin Dial 3: 187, 1990

    Google Scholar 

  265. Heel RC, Brogden RN, Speight TM, Avery GS: Butorphanol: a review of its pharmacological properties and therapeutic efficacy. Drugs 16: 473, 1978

    PubMed  CAS  Google Scholar 

  266. Barnes JN, Williams AJ, Tomson MJ, Toseland PA, Goodwin PJ: Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs. Br Med J 290(6470)L 740, 1985

    CAS  Google Scholar 

  267. Mather LE: Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet 8: 422, 1983

    PubMed  CAS  Google Scholar 

  268. Szeto HH, Inturrisi CE, Houde R, Saal S, Cheigh J. Reidenberg MM: Accumulation of normeperidine, and active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 86: 738, 1977

    PubMed  CAS  Google Scholar 

  269. Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M: Methadone use in patients with chronic renal disease. Drug Alcohol Depend 5: 197, 1980

    PubMed  CAS  Google Scholar 

  270. Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P: Morphine pharmacokinetics in renal failure. Anesthesiology 66: 327, 1987

    PubMed  CAS  Google Scholar 

  271. Säwe J, Odar-Cederlöf I: Kinetics of morphine in patients with renal failure. Eur J Clin Pharmacol 32: 377, 1987

    PubMed  Google Scholar 

  272. Giacomini KM, Gibson TP, Levy G: Effect of hemodialysis on propoxyphene and norpropoxyphenne concentrations in blood of anephric patients. Clin Pharmacol Ther 27: 508, 1980

    Article  PubMed  CAS  Google Scholar 

  273. Clissold SP: Paracetamol and phenacetin. Drugs 32(Suppl 4): 46, 1986

    PubMed  Google Scholar 

  274. Prescott LF, Speirs GC, Critchley JA, Temple RM, Winney RJ: Paracetamol disposition and metabolite kinetics in patients with chronic renal failure. Eur J Clin Pharmacol 36: 291, 1989

    PubMed  CAS  Google Scholar 

  275. Needs CJ, Brooks PM: Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet 10: 164, 1985

    PubMed  CAS  Google Scholar 

  276. Agoston S, Vandenbrom RH, Wierda JM: Clinical pharmacokinetics of neuromuscular blocking drugs. Clin Pharmacokinet 22: 94, 1992

    PubMed  CAS  Google Scholar 

  277. Davis PJ, Cook DR: Clinical pharmacokinetics of the newer intravenous anaesthetic agents. Clin Pharmacokinet 11: 18, 1986

    PubMed  CAS  Google Scholar 

  278. Pollard BJ: Editorial: neuromuscular blocking drugs and renal failure. Br J Anaesth 68: 545, 1992

    PubMed  CAS  Google Scholar 

  279. Gramstad L: Atracurium, vecuronium and pancuronium in end-stage renal failure. Dose-response properties and interactions with azathioprine. Br J Anaesth 59: 995, 1987

    PubMed  CAS  Google Scholar 

  280. Mongin-Long D, Chabrol B, Baude C et al.: Atracurium in patients with renal failure. Clinical trial of a new neuromuscular blocker. Br J Anaesth 58(Suppl): 44S, 1986

    Google Scholar 

  281. Ramzan MI, Shanks CA, Triggs EJ: Gallamine disposition in surgical patients with chronic renal failure. J Clin Pharmacol 12: 141, 1981

    CAS  Google Scholar 

  282. Brotherton WP, Matteo RS: Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. Anesthesiology 55: 273, 1981

    PubMed  CAS  Google Scholar 

  283. Aquilonius SM, Hartvig P: Clinical pharmacokinetics of cholinesterase inhibitors. Clin Pharmacokinet 11: 236, 1986

    PubMed  CAS  Google Scholar 

  284. McLeod K, Watson MJ, Rawlins MD: Pharmacokinetics of pancuronium in patients with normal and impaired renal function. Br J Anaesth 48: 341, 1976

    PubMed  CAS  Google Scholar 

  285. Kirvela M, Olkkola KT, Rosenberg PH, Yli-Hankala A, Salmela K, Lingren L: Pharmacokineties of propofol and haemodynamic changes during induction of anaesthesia in uraemic patients. Br J Anaesth 68: 178, 1992

    PubMed  CAS  Google Scholar 

  286. Cronnelly R, Stanski DR, Miller RD, Sheiner LB: Pyridostigmine kinetics with and without renal function. Clin Pharmacol Ther 28: 78, 1980

    Article  PubMed  CAS  Google Scholar 

  287. Bishop M, Hornbein TF: Prolonged effect of succinylcholine after neostigmine and pyridostigmine administration in patients with renal failure. Anesthesiology 58: 384, 1983

    Article  PubMed  CAS  Google Scholar 

  288. Matteo RS. Nishitateno K, Pua EK, Spector S: Pharmacokinetics of d-tubocurarine in man: effect of an osmotic diuretic on urinary excretion. Anesthesiology 52: 335, 1980

    PubMed  CAS  Google Scholar 

  289. Lynam DP, Cronnelly R, Castagnoli KP et al.: The pharmacodynamics and pharmacokinetics of vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure. Anesthesiology 69: 227, 1988

    PubMed  CAS  Google Scholar 

  290. Hulter HN, Licht JH, Ilnicki LP, Singh S: Clinical efficacy and pharmacokinetics of clonidine in hemodialysis and renal insufficiency. J Lab Clin Med 94: 223, 1979

    PubMed  CAS  Google Scholar 

  291. Lowenthal DT, Matzek KM, MacGregor TR: Clinical pharmacokinetics of clonidine. Clin Pharmacokinet 14: 287, 1988

    PubMed  CAS  Google Scholar 

  292. Carlson RV, Bailey RR, Begg EJ, Cowlishaw MG, Sharman JR: Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure. Clin Pharmacol Ther 40: 561, 1986

    Article  PubMed  CAS  Google Scholar 

  293. Young RA, Brogden RN: Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension. Drugs 35: 525, 1988

    PubMed  CAS  Google Scholar 

  294. Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS: Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 26: 212, 1983

    PubMed  CAS  Google Scholar 

  295. Finnerty FA, Brogden RN: Guanadrel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs 30: 22. 1985

    PubMed  Google Scholar 

  296. Halstenson CE, Opsahl JA, Abraham PA et al.: Disposition of guanadrel in subjects with normal and impaired renal function. J Clin Pharmacol 29: 128, 1989

    PubMed  CAS  Google Scholar 

  297. Carchman SH, Sica DA, Davis J et al.: Steady-state plasma levels and pharmacokinetics of guanfacine in patients with renal insufficiency. Nephron 53: 18, 1989

    PubMed  CAS  Google Scholar 

  298. Sorkin EM, Heel RC: Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 31:301, 1986

    PubMed  CAS  Google Scholar 

  299. Myhre E, Rugstad HE, Hansen T: Clinical pharmacokinetics of methyldopa. Clin Pharmacokinet 7: 221, 1982

    PubMed  CAS  Google Scholar 

  300. Lameire N, Gordts J: A pharmacokinetic study of prazosin in patients with varying degrees of chronic renal failure. Eur J Clin Pharmacol 31: 333, 1986

    PubMed  CAS  Google Scholar 

  301. Vincent J, Meredith PA, Reid JL, Elliot HL, Rubin PC: Clinical pharmacokinetics of prazosin — 1985. Clin Pharmacokinet 10: 144, 1985

    PubMed  CAS  Google Scholar 

  302. Zsoter TT, Johnson GE, DeVeber GA, Paul H: Excretion and metabolism of reserpine in renal failure. Clin Pharmacol Ther 14: 325, 1973

    PubMed  CAS  Google Scholar 

  303. Jungers P, Ganeval D, Pertuiset N, Chaveau P: Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. Am J Med 80(Suppl 5B): 94, 1986

    PubMed  CAS  Google Scholar 

  304. Hoyer J, Schulte KL, Lenz T: Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin Pharmacokinet 24: 230, 1993

    PubMed  CAS  Google Scholar 

  305. Balfour JA, Goa KL: Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs 42: 511, 1991

    PubMed  CAS  Google Scholar 

  306. Brogden RN, Todd PA, Sorkin EM: Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 36: 540, 1988

    PubMed  CAS  Google Scholar 

  307. Duchin KL, Pierides AM, Heald A, Signhvl HM, Rommel AAJ: Elimination kinetics of captopril in patients with renal failure. Kidney Int 25: 942, 1984

    PubMed  CAS  Google Scholar 

  308. Fujimura A, Kajiyama H, Ebihara A, Iwashita K, Nomura Y, Kawahara Y: Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis. Nephron 44: 324, 1986

    PubMed  CAS  Google Scholar 

  309. Fruncillo RJ, Rocci ML Jr, Vlasses PH et al.: Disposition of enalapril and enalaprilat in renal insufficiency. Kidney Int 31(Suppl 20): S117, 1987

    Google Scholar 

  310. Todd PA, Goa KL: Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 43: 346, 1992

    PubMed  CAS  Google Scholar 

  311. Gehr TW, Sica DA, Grasela DM, Fakhry I, Davis J, Duchin KL: Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. Eur J Clin Pharmacol 41: 165, 1991

    PubMed  CAS  Google Scholar 

  312. Hui KK, Duchin KL, Kripalani KJ, Chan D, Kramer PK, Yanagawa N: Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther 49: 457, 1991

    Article  PubMed  CAS  Google Scholar 

  313. Murdoch D, McTavish D: Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. Drugs 43: 123, 1992

    PubMed  CAS  Google Scholar 

  314. Lancaster SG, Todd PA: Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 35: 646, 1988

    PubMed  CAS  Google Scholar 

  315. van Schaik BA, Geyskes GG, van der Wouw PA, van Rooij HH, Porsius AJ: Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function. Eur J Clin Pharmacol 34: 61, 1988

    PubMed  Google Scholar 

  316. Halstenson CE, Opsahl JA, Rachael K et al.: The pharma-cokinetics of quinapril and its active metabolite quinaprilat in patients with varying degrees Rnal function. J Clin Pharmacol 32: 344, 1992

    PubMed  CAS  Google Scholar 

  317. Schunkert H, Kindler J, Gassmann M et al.: Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. Eur J Clin Pharmacol 37: 249, 1989

    PubMed  CAS  Google Scholar 

  318. Todd PA, Benfield P: Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 39: 110, 1990

    PubMed  CAS  Google Scholar 

  319. Gill J, Heel RC, Fitton A: Amiodarone: an overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 43: 69, 1992

    PubMed  CAS  Google Scholar 

  320. Josselson J, Narang PK, Adir J, Yacobi A, Sadler JH: Bretylium kinetics in renal insufficiency. Clin Pharmacol Ther 33: 144, 1983

    Article  PubMed  CAS  Google Scholar 

  321. Rapeport WG: Clinical pharmacokinetics of bretylium. Clin Pharmacokinet 10: 248, 1985

    PubMed  CAS  Google Scholar 

  322. Brogden RN, Todd PA: Disopyramide: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias. Drugs 34: 151, 1986

    Google Scholar 

  323. Burk M, Peters U: Disopyramide kinetics in renal impairment: determinants of interindividual variability. Clin Pharmacol Ther 34: 331, 1983

    Article  PubMed  CAS  Google Scholar 

  324. Haughey DB, Kraft CJ, Matzke GR, Keane WF, Halstenson CE: Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. Am J Nephrol 5: 35, 1985

    PubMed  CAS  Google Scholar 

  325. Bergstrand RH, Wang T, Roden DM et al.: Encainide disposition in patients with renal failure. Clin Pharmacol Ther 40: 64, 1986

    Article  PubMed  CAS  Google Scholar 

  326. Brogden RN, Todd PA: Encainide: a review of its pharmacological properties and therapeutic efficacy. Drugs 34:519, 1987

    PubMed  CAS  Google Scholar 

  327. Forland SC, Burgess E, Blair AD et al.: Oral flecainide pharmacokinetics in patients with impaired renal function. J Clin Pharmacol 28: 259, 1988

    PubMed  CAS  Google Scholar 

  328. Forland SC, Cutler RE, McQuinn RL et al.: Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. J Clin Pharmacol 28: 727, 1988

    PubMed  CAS  Google Scholar 

  329. Bennett PN, Aarons LJ, Bending MR, Steiner JA, Rowland M: Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man. J Pharmacokinet Biopharm 10: 265, 1982

    PubMed  CAS  Google Scholar 

  330. Eiriksson CE, Brogden RN: Lorcainide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 27: 279, 1984

    PubMed  CAS  Google Scholar 

  331. Monk JP, Brogden RN: Mexiletine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs 40: 374, 1990

    PubMed  CAS  Google Scholar 

  332. Wang T, Wuellner D, Woosley RL, Stone WJ: Pharmacokinetics and nondialyzability of mexiletine in renal failure. Clin Pharmacol Ther 37: 649, 1988

    Article  Google Scholar 

  333. Fitton A, Buckley MT: Moricizine: a review of its pharmacological properties, and therapeutic efficacy in cardiac arrhythmias. Drugs 40: 138, 1990

    PubMed  CAS  Google Scholar 

  334. Pieniaszek HJ, McEntegart CM, Mayersohn M, Michael UF: Moricizine pharmacokinetics in renal insufficiency: reevaluation of elimination half-life. J Clin Pharmacol 32: 412, 1992

    PubMed  Google Scholar 

  335. Stec GP, Atkinson AJ, Nevin MJ et al.: N-actylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis. Clin Pharmacol Ther 26: 618, 1979

    PubMed  CAS  Google Scholar 

  336. Harron DW, Brogden RN: Acecainide (N-acetylprocainamide): a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. Drugs 39: 720, 1990

    PubMed  CAS  Google Scholar 

  337. Raehl CL, Moorthy AV, Beirne GJ: Procainamide pharmacokinetics in patients on continuous ambulatory’ peritoneal dialysis. Nephron 44: 191, 1986

    PubMed  CAS  Google Scholar 

  338. Bryson HM, Palmer KJ, Langtry HD, Fitton A: Propafenone: a reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Drugs 45: 85, 1993

    PubMed  CAS  Google Scholar 

  339. Burgess E, Duff H, Wilkes P: Propafenone disposition in renal insufficiency and renal failure. J Clin Pharmacol 29: 112, 1989

    PubMed  CAS  Google Scholar 

  340. Crevasse L: Quinidine: an update on therapeutics, pharmacokinetics and serum concentration monitoring. Am J Cardiol 62: 221, 1988

    Google Scholar 

  341. Kessler KM, Perez GO: Decreased quinidine plasma protein binding during hemodialysis. Clin Pharmacol Ther 30: 121, 1981

    Article  PubMed  CAS  Google Scholar 

  342. Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS: Tocainide: a review of its pharmacological properties and therapeutic efficacy. Drugs 26: 93, 1983

    PubMed  CAS  Google Scholar 

  343. Rachl CL, Beirne GJ, Moorthy AV, Patel AK: Tocainide pharmacokinetics during continuous ambulatory peritoneal dialysis. Am J Cardiol 60: 747, 1987

    Google Scholar 

  344. Wiegers U, Hanrath P, Kuck KH et al.: Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. Eur J Clin Pharmacol 24: 503, 1983

    PubMed  CAS  Google Scholar 

  345. Borehard U: Pharmacokineties of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance. Clin Physiol Biochem 8(Suppl 2): 28, 1990

    Google Scholar 

  346. Riddell JG, Harron DW, Shanks RG: Clinical pharmacokinetics of β-adrenoceptor antagonists. An update. Clin Pharmacokinet 12: 305, 1987

    PubMed  CAS  Google Scholar 

  347. Kirch W, Köhler H, Berggren G, Braun W: The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetylmetabolite. ClinNephrol 18: 88, 1982

    CAS  Google Scholar 

  348. Roux A, Aubert P, Guedon J, Flouvat B: Pharmacokineties of acebutolol in patients with all grades of renal failure. Eur J Clin Pharmacol 17: 339, 1980

    PubMed  CAS  Google Scholar 

  349. Singh BN, Thoden WR, Ward A: Acebutolol: a review of pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia. Drugs 29: 531, 1985

    PubMed  CAS  Google Scholar 

  350. Kirch W, Kohler H, Mutschler E, Schafer M: Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol 19: 65, 1981

    PubMed  CAS  Google Scholar 

  351. Wadworth A, Murdoch D, Brogden RN: Atenolol: a reappraisal of its pharmacological properties, and therapeutic use in cardiovascular disorders. Drugs 42: 468, 1991

    PubMed  CAS  Google Scholar 

  352. Beresford R, Heel RC: Betaxolol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension. drugs 31: 6, 1986

    PubMed  CAS  Google Scholar 

  353. Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y: Pharmacokinetics of carteolol in patients with impaired renal function. Eur J Clin Pharmacol 43: 417, 1992

    PubMed  CAS  Google Scholar 

  354. Hasenfub G, Schafer-Korting M, Knauf H, Mutschler E, Just H: Pharmacokinetics of carteolol in relation to renal function. Eur J Clin Pharmacol 29: 461, 1985

    Google Scholar 

  355. Chrisp P, Goa KL: Dilevalol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension. Drugs 30: 234, 1990

    Google Scholar 

  356. Kelly JG, Laher MS, Donohue J, Doyle GD: The pharmacokinetics of dilevalol in renal impairment. J Hum Hypertens 4(Suppl 2): 59, 1990

    PubMed  Google Scholar 

  357. Benfield P, Sorkin EM: Esmolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 33: 392, 1987

    PubMed  CAS  Google Scholar 

  358. Flaherty JF, Wong B, LaFollette G, Warnock DG, Hulse JD, Gambertoglio JG: Pharmacokinetics of esmolol and ASL-8123 in renal failure. Clin Pharmacol Ther 45: 321, 1989

    Article  PubMed  CAS  Google Scholar 

  359. Goa KL, Benfield P, Sorkin EM: Labetalol: a reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischemic heart disease. Drugs 37: 583, 1989

    PubMed  CAS  Google Scholar 

  360. Halstenson CE, Opsahl JA, Pence TV et al.: The disposition and dynamics of labetalol in patients on dialysis. Clin Pharmacol Ther 40: 462, 1986

    Article  PubMed  CAS  Google Scholar 

  361. Regardh CG, Johnsson G: Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet 5: 557, 1980

    PubMed  CAS  Google Scholar 

  362. Dreyfuss J, Griffith DL, Singhvi SM et al.: Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single-and multiple-dosage regimens to hypertensive patients. J Clin Pharmacol 19: 712, 1979

    PubMed  CAS  Google Scholar 

  363. Frishman WH: Nadolol: a new B-adrenoceptor antagonist. N Engl J Med 305: 678, 1981

    Article  PubMed  CAS  Google Scholar 

  364. Bernard N, Cuisinaud G, Pozet N, Zech PY, Sassard J: Pharmacokinetics of penbutolol and its metabolites in renal insufficiency. Eur J Clin Pharmacol 29: 215, 1985

    PubMed  CAS  Google Scholar 

  365. Ohnhaus EE, Heidemann H, Meier J, Maurer G: Metabolism of pindolol in patients with renal failure. Eur J Clin Pharmacol 22: 423, 1982

    PubMed  CAS  Google Scholar 

  366. Stone WJ, Walle T: Massive propranolol metabolite retention during maintenance hemodialysis. Clin Pharmacol Ther 28:449, 1980

    Article  PubMed  CAS  Google Scholar 

  367. Wood AJ, Vestal RE, Spannuth CL, Stone WJ, Wilkinson GR, Shand DG: Propranolol disposition in renal failure. Br J Clin Pharmacol 10: 561, 1980

    PubMed  CAS  Google Scholar 

  368. Blair AD, Burgess ED, Maxwell BM, Cutler RE: Sotalol kinetics in renal insufficiency. Clin Pharmacol Ther 29: 457, 1981

    Article  PubMed  CAS  Google Scholar 

  369. Singh BN, Deedwania P, Koonlawee N, Ward A, Sorkim EM: Sotalol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 34: 311, 1987

    PubMed  CAS  Google Scholar 

  370. Kelly JG, O’Malley K: Clinical pharmacokinetics of calcium antagonists. An update. Clin Pharmacokinet 22: 416, 1992

    PubMed  CAS  Google Scholar 

  371. Laher MS, Kelly JG, Doyle GD et al.: Pharmacokinetics of amlodipine in renal impairment. J Cardiovasc Pharmacol 12(Suppl 7): S60, 1988

    Google Scholar 

  372. Buckley MM, Grant SM, Goa KL, McTavish D, Sorkin EM: Diltiazem. A reappraisal of its pharmacological properties and therapeutic use. Drugs 39: 757, 1990

    PubMed  CAS  Google Scholar 

  373. Grech-Bélangér O, Langlois S, LeBoeuf E: Pharmacokinetics of diltiazem in patients undergoing continuous ambulatory peritoneal dialysis. J Clin Pharmacol 28: 477. 1988

    PubMed  Google Scholar 

  374. Pozet N, Brazier JL, Aïssa AH et al.: Pharmacokinetics of diltiazem in severe renal failure. Eur J Clin Pharmacol 24: 635, 1983

    PubMed  CAS  Google Scholar 

  375. Buur T, Larsson R, Regårdh CG. Aberg J: Pharmacokinetics of felodipine in chronic hemodialysis patients. J Clin Pharmacol 31: 709, 1991

    PubMed  CAS  Google Scholar 

  376. Edgar B, Regardh CG, Attman PO, Aurell M, Herlitz H. Johnsson G: Pharmacokinetics of felodinine in patients with impaired renal function. Br J Clin Pharmacol 27: 67, 1989

    PubMed  CAS  Google Scholar 

  377. Todd PA, Faulds D: Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs 44: 251, 1992

    PubMed  CAS  Google Scholar 

  378. Chandler MH, Schran HF, Cutler RE, Smith AJ. Gonasun LM, Blouin RA: The effeets of renal function on the disposition of isradipine. J Clin Pharmacol 28: 1076, 1988

    PubMed  CAS  Google Scholar 

  379. Fitton A, Benfield P: Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 40: 31, 1990

    PubMed  CAS  Google Scholar 

  380. Schonholzer K, Marone C: Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients. Eur J Clin Pharmacol 42: 231, 1992

    PubMed  CAS  Google Scholar 

  381. Sorkin EM, Clissold SP: Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 33: 296, 1987

    PubMed  CAS  Google Scholar 

  382. Martre H, Sari R, Taburet AM, Jacobs C, Singlas E: Haemodialysis does not affect the pharmacokinetics of nifedipine. Br J Clin Pharmacol 20: 155, 1985

    PubMed  CAS  Google Scholar 

  383. Sorkin EM, Clissold SP, Brogden RN: Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 30: 182, 1985

    PubMed  CAS  Google Scholar 

  384. Goa KL, Sorkin EM: Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 33: 123, 1987

    PubMed  CAS  Google Scholar 

  385. Mikus G, Mast V, Fischer C, Machleidt C, Kuhlman U, Eichelbaum M: Pharmacokineties, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension. Br J Clin Pharmacol 31: 313, 1991

    PubMed  CAS  Google Scholar 

  386. Hanyok JJ, Chow MS, Kluger J, Izard MW: An evaluation of the pharmacokinetics, pharmacodynamics, anddialyzability of verapamil in chronic hemodialysis patients. J Clin Pharmacol 28: 831, 1988

    PubMed  CAS  Google Scholar 

  387. McTavish D, Sorkin EM: Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs 38: 19, 1989

    PubMed  CAS  Google Scholar 

  388. Mooy J, Schols M, van Baak M, van Hooff M, Muytens A, Rahn KH: Pharmacokinetics of verapamil in patients with renal failure. Eur J Clin Pharmacol 28: 405, 1985

    PubMed  CAS  Google Scholar 

  389. Graves PE, Fenster PE, MacFarland RT, Marcus FI, Perrier D: Kinetics of digitoxin and the bis-and monodigitoxosides of digitoxigenin in renal insufficiency. Clin Pharmacol Ther 36: 607, 1984

    Article  PubMed  CAS  Google Scholar 

  390. Vohringer HF, Rietbrock N: Digitalis therapy in renal failure with special regard to digitoxin. Int J Clin Pharmacol Ther Toxicol 19: 175, 1981

    PubMed  CAS  Google Scholar 

  391. Gibson TP, Nelson HA: The question of cumulation of digoxin metabolites in renal failure. Clin Pharmacol Ther 27: 219, 1980

    Article  PubMed  CAS  Google Scholar 

  392. Keller F, Molzahn M, Ingerowski R: Digoxin dosage in renal insufficiency: impracticality of basing it on the creatinine clearance, body weight and volume of distribution. Eur J Clin Pharmacol 18: 433, 1980

    PubMed  CAS  Google Scholar 

  393. Sonnenblick M, Abraham AS, Meshulam Z, Eylath U: Correlation between manifestations of digoxin toxicity and serum digoxin, calcium, potassium, and magnesium concentrations and arterial pH. Br Med J 286: 1089, 1983

    CAS  Google Scholar 

  394. Lant A: Diuretics. Clinical pharmacology and therapeutic use (Part I). Drugs 29: 57, 1985

    PubMed  CAS  Google Scholar 

  395. Lant A: Diuretics. Clinical pharmacology and therapeutic use (Part II). Drugs 29: 162, 1985

    PubMed  CAS  Google Scholar 

  396. Chapron DJ, Gomolin IH, Sweeney KR: Acetazolamide blood concentrations are excessive in the elderly: propensity for acidosis and relationship to renal function. J Clin Pharmacol 29: 348, 1989

    PubMed  CAS  Google Scholar 

  397. Spahn H, Reuter K, Mutschler E, Gerok W, Knauf H: Pharmacokinetics of amiloride in renal and hepatic disease. Eur J Clin Pharmacol 33: 493, 1987

    PubMed  CAS  Google Scholar 

  398. Pentikäinen PJ, Pasternack A, Lampainen E, Neuvonen PJ, Pentilla A: Bumetanide kinetics in renal failure. Clin Pharmacol Ther 37: 582, 1985

    Article  PubMed  Google Scholar 

  399. Ward A, Heel RC: Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 28: 426, 1984

    PubMed  CAS  Google Scholar 

  400. Mulley BA, Parr GD, Rye RM: Pharmacokinetics of chlorthalidone. Eur J Clin Pharmacol 17: 203, 1980

    PubMed  CAS  Google Scholar 

  401. Pillay VK, Schwartz FD, Aimi K, Kark RM: Transient and permanent deafness following treatment of ethacrynic acid in renal failure. Lancet 1(585), 77, 1969

    PubMed  CAS  Google Scholar 

  402. Brater DC, Anderson SA, Brown-Cartwright D: Response to furosemide in chronic renal insufficiency: rationale for limited doses. Clin Pharmacol Ther 40: 134, 1986

    Article  PubMed  CAS  Google Scholar 

  403. Ponto LL, Schoenwald RD: Furosemide (Frusemide). A pharmacokinetic/pharmacodynamic review (Part I). Clin Pharmacokinet 18: 381, 1990

    PubMed  CAS  Google Scholar 

  404. Traeger A, Stein G, Sperschneider H, Keil E: Pharmacokinetic and pharmacodynemic effects of furosemide in patients with impaired renal function. Int J Clin Pharmacol Ther Toxicol 22: 481, 1984

    PubMed  CAS  Google Scholar 

  405. Acchiardo SR, Skoutakis VA: Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment. Am Heart J 106: 237, 1983

    PubMed  CAS  Google Scholar 

  406. Clissold SP, Brogden RN: Piretanide. A preliminary review of its pharmacodynamic and pharmcokinetic properties, and therapeutic efficacy. Drugs 29: 489, 1985

    PubMed  CAS  Google Scholar 

  407. Marone C, Reubi FC, Perisic M, Lahn W: Pharmacokinetics of high doses of piretanide in moderate to severe renal failure. Eur J Clin Pharmacol 27: 589, 1984

    PubMed  CAS  Google Scholar 

  408. Skluth HA, Gums JG: Spironolactone: a re-examination. DICP Ann. Pharmacother 24: 52, 1990

    CAS  Google Scholar 

  409. Niemeyer C, Hasenfub G, Wais U, Knauf H, Shafer-Korting M, Mutschler E: Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur J Clin Pharmacol 24: 661, 1983

    PubMed  CAS  Google Scholar 

  410. Fairley KF, Woo KT, Birch DF, Leaker BR, Ratnaike S: Triamterene-induced crystalluria and cylinduria: clinical and experimental studies. Clin Nephrol 26: 169, 1986

    PubMed  CAS  Google Scholar 

  411. Bottorff MB, Rutledge DR, Pieper JA: Evaluation of intravenous amrinone: the first of a new class of positive inotropic agents with vasodilator properties. Pharmacotherapy 5: 227, 1985

    PubMed  CAS  Google Scholar 

  412. Ward A, Brogden RN, Heel RC, Speight TM, Avery GS: Amrinone: a preliminary review of its pharmacological properties and therapeutic use. Drugs 26: 468, 1983

    PubMed  CAS  Google Scholar 

  413. Majerus TC, Dasta JF, Bauman JL, Danzinger LH, Ruffolo RR: Dobutamine; ten years later. Pharmacotherapy 9: 245, 1989

    PubMed  CAS  Google Scholar 

  414. Sonnenblick EH, Frishman WH, LeJemtel TH: Dobutamine; a new synthetic cardioactive sympathetic amine. N Engl J Med 300: 17, 1979

    Article  PubMed  CAS  Google Scholar 

  415. Larsson R, Liedholm H, Andersson KE, Keane MA, Henry G: Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment. Eur J Clin Pharmacol 29: 549, 1986

    PubMed  CAS  Google Scholar 

  416. Young RA, Ward A: Milrinone: a preliminary review of its pharmacological properties and therapeutic use. Drugs 36: 158, 1988

    PubMed  CAS  Google Scholar 

  417. Bogaert MG: Clinical pharmacokinetics of glyceryl trinitrate following the use of systemic and topical preparations. Clin Pharmacokinet 12: 1, 1987

    PubMed  CAS  Google Scholar 

  418. Evers J, Bonn R, Boertz A et al.: Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis. Eur J Clin Pharmacol 32: 503, 1987

    PubMed  CAS  Google Scholar 

  419. Evers J, Krakamp B, Klimkait W et al.: Pharmacokinetics of isosorbide-5-nitrate in renal failure. Eur J Cl Pharmacol 30: 349, 1986

    CAS  Google Scholar 

  420. Pearson RM: Pharmacokinetics and response to diazoxide in renal failure. Clin Pharmacokinet 2: 198, 1977

    PubMed  CAS  Google Scholar 

  421. Ludden TM, McNay JL, Shepherd AM, Lin MS: Clinical pharmacokinetics of hydralazine. Clin Pharmacokinet 7: 185, 1982

    PubMed  CAS  Google Scholar 

  422. Halstenson CE, Opsahl JA, Wright CE et al.: Disposition of minoxidil in patients with various degrees of renal function. J Clin Pharmacol 29: 798, 1989

    PubMed  CAS  Google Scholar 

  423. Rindone JP, Sloane EP: Cyanide toxicity from sodium nitroprusside: risks and management. Ann Pharmacother 26: 515, 1992

    PubMed  CAS  Google Scholar 

  424. Schulz V: Clinical pharmacokinetics of nitroprusside cyanide thiosulphate and thiocyanate. Clin Pharmacokinet 9: 239, 1984

    PubMed  CAS  Google Scholar 

  425. Crooke ST, Comis RL, Einhorn LH, Strong JE, Broughton A, Prestayko AW: Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an IV bolus. Cancer Treat Rep 61: 1631, 1977

    PubMed  CAS  Google Scholar 

  426. Ehrsson H, Hassan M, Ehrnebo M, Beran M: Busulfan kinetics. Clin Pharmacol Ther 34: 86, 1983

    Article  PubMed  CAS  Google Scholar 

  427. Elferink F, van der Vijgh WJ, Klein I, ten Bokkel Huinink WW, Dubbelman R, McVie JG: Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 21: 57, 1988

    PubMed  CAS  Google Scholar 

  428. Motzer RJ, Niedzwiecki D, Isaacs M et al.: Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. Cancer Chemother Pharmacol 27: 234, 1990

    PubMed  CAS  Google Scholar 

  429. Van der Vijgh WJ: Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21: 242, 1991

    PubMed  Google Scholar 

  430. Newell DR, Calvert AH, Harrap KR, McElwain TJ: Studies on the pharmacokinetics of chlorambucil and prednimustine in man. Br J Clin Pharmacol 15: 253, 1983

    PubMed  CAS  Google Scholar 

  431. Blachley JD, Hill JB: Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 95: 628, 1981

    PubMed  CAS  Google Scholar 

  432. Corden BJ, Fine RL, Ozols RF, Collins JM: Clinical pharmacology of high-dose cisplatin. Cancer Chemother Pharmacol 14: 38, 1985

    PubMed  CAS  Google Scholar 

  433. Juma FD, Rogers HJ, Trounce JR: Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 19: 443, 1981

    PubMed  CAS  Google Scholar 

  434. Moore MJ: Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 20: 194, 1991

    PubMed  CAS  Google Scholar 

  435. Wang LH, Lee CS, Majeske BL, Marbury TC: Clearance and recovery calculations in hemodialysis: application to plasma, red blood cell, and dialysate measurements for cyclophosphamide. Clin Pharmacol Ther 29: 365, 1981

    Article  PubMed  CAS  Google Scholar 

  436. Damon LE, Mass R, Linker CA: The association between high-dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 7: 1563, 1989

    PubMed  CAS  Google Scholar 

  437. Goto M, Yoshida H, Honda A et al.: Delayed disposition of adriamycin and its active metabolite in haemodialysis patients. (Letter) Eur J Clin Pharmacol 44: 301, 1993

    PubMed  CAS  Google Scholar 

  438. Speth PA, van Hoesel QG, Haanen C: Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15: 15, 1988

    PubMed  CAS  Google Scholar 

  439. Henwood JM, Brogden RN: Etoposide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 39: 438, 1990

    PubMed  CAS  Google Scholar 

  440. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215, 1989

    PubMed  CAS  Google Scholar 

  441. Hollingshead LM, Faulds D: Idarubicin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 42: 690, 1991

    PubMed  CAS  Google Scholar 

  442. Alberts DS, Chen HG, Benz D, Mason NL: Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. Br J Cancer 43: 330, 1981

    PubMed  CAS  Google Scholar 

  443. Österborg A, Ehrsson H, Eksborg S. Wallin I, Mellstedt H: Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients. EurJ Cancer Clin Oncol 25: 899, 1989

    Google Scholar 

  444. Sand TE, Jacobsen S: Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol 19: 453, 1981

    PubMed  CAS  Google Scholar 

  445. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA: The pharmacology and clinical use of methotrexate. N Engl J Med 309: 1094, 1983

    Article  PubMed  CAS  Google Scholar 

  446. Shen DD, Azarnoff DL: Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 3: 1, 1978

    PubMed  CAS  Google Scholar 

  447. Den Hartigh J, McVie JG, Van Oort WS, Pinedo HM: Pharmacokinetics of mitomycin C in humans. Cancer Res 43: 5017, 1983

    Google Scholar 

  448. Ellis ME, Weiss RB, Kuperminc M: Nephrotoxicity of lomustine: a case report and literature review, Cancer Chemother Pharmacol 15: 174, 1985

    PubMed  CAS  Google Scholar 

  449. Oliverio VT: Toxicology and pharmacology of the nitrosoureas. Cancer Chemother Rep 413, 1973

    Google Scholar 

  450. Kennedy BJ: Metabolic and toxic effects of mithramycin during tumor therapy. Am J Med 49: 494, 1970

    PubMed  CAS  Google Scholar 

  451. Hall-Craggs M, Brenner DE, Vigorito RD, Sutherland JC: Acute renal failure and renal tubular squamous metaplasia following treatment with streptozocin. Hum Pathol 13: 597, 1982

    PubMed  CAS  Google Scholar 

  452. Buckley MM, Goa KL: Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 37: 451, 1989

    PubMed  CAS  Google Scholar 

  453. Owellen RJ, Hartke CA, Hains FO: Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 37: 2597, 1977

    PubMed  CAS  Google Scholar 

  454. Clissold SP, Edwards C: Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35: 214, 1988

    PubMed  CAS  Google Scholar 

  455. Ferner RE, Chaplin S: The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clin Pharmacokinet 12: 379, 1987

    PubMed  CAS  Google Scholar 

  456. Palmer KJ, Brogden RN: Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 46: 92, 1993

    PubMed  CAS  Google Scholar 

  457. Lebovitz HE: Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacotherapy 5: 63, 1985

    PubMed  CAS  Google Scholar 

  458. Feldman JM: Glyburide: a second-generation sulfonylurea hypoglycemic agent. Pharmacotherapy 5: 43, 1985

    PubMed  CAS  Google Scholar 

  459. Brogden RN, Heel RC: Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use. Drugs 34: 350, 1987

    PubMed  CAS  Google Scholar 

  460. Guba EA, Abel SR, Golper TA: Practical guidelines for drug therapy in dialysis: lipid lowering agents. Semin Dial 2: 186, 1989

    Google Scholar 

  461. Sherrard DJ, Goldberg AB, Haas LB, Brunzell JD: Chronic clofibrate therapy in maintenance hemodialysis patients. Nephron 25: 219, 1980

    PubMed  CAS  Google Scholar 

  462. Tse FL, Jaffe JM, Troendle A: Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 32: 630, 1992

    PubMed  CAS  Google Scholar 

  463. Manninen V, Malkonen M, Esailo A: Gemfibrozil treatment of dyslipidaemias in renal failure with uraemia or in the nephrotic syndrome. Res Clin Forums 4: 113, 1982

    Google Scholar 

  464. Corpier CL, Jones PH, Suki WN et al.: Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 260: 239, 1988

    PubMed  CAS  Google Scholar 

  465. Henwood JM, Heel RC: Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 36: 429, 1988

    PubMed  CAS  Google Scholar 

  466. Figge HL, Figge J, Souney PF, Mutnick AH, Sacks F: Nicotinic acid: a review of its clinical use in the treatment of lipid disorders. Pharmacotherapy 8: 287, 1988

    PubMed  CAS  Google Scholar 

  467. McTavish D, Sorkin EM: Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 42: 65, 1991

    PubMed  CAS  Google Scholar 

  468. Buckley MM, Goa KL, Price AH, Brogden RN: Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs 37: 761, 1989

    PubMed  CAS  Google Scholar 

  469. Mauro VF: Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 24: 195, 1993

    PubMed  CAS  Google Scholar 

  470. Kampmann JP, Hansen JM: Clinical pharmacokinetics of antithyroid drugs. Clin Pharmacokinet 6: 401, 1981

    PubMed  CAS  Google Scholar 

  471. Jansson R, Lindstrom B, Dahlberg PA: Pharmacokinetic properties and bioavailability of methimazole. Clin Pharmacokinet 10: 443, 1985

    Article  PubMed  CAS  Google Scholar 

  472. Lauritsen K, Laursen LS, Rask-Madsen J: Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part I). Clin Pharmacokinet 19: 11, 1990

    PubMed  CAS  Google Scholar 

  473. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC: Metoclopramide: an updated review of its pharmacological properties and clinical use. Drugs 25: 451, 1983

    PubMed  CAS  Google Scholar 

  474. Milne RJ, Heel RC: Ondansetron: therapeutic use as an antiemetic. Drugs 41: 574, 1991

    PubMed  CAS  Google Scholar 

  475. Lin JH: Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antonists. Relationship between intrinsic potency and effective plasma concentrations. Clin Pharmacokinet 20: 218, 1991

    PubMed  CAS  Google Scholar 

  476. Somogyi A, Gugler R: Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet 8: 463, 1983

    PubMed  CAS  Google Scholar 

  477. Larsson R, Bodemar G, Norlander B: Oral absorption of cimetidine and its clearance in patients with renal failure. Eur J Clin Pharmacol 15: 153, 1979

    PubMed  CAS  Google Scholar 

  478. Larsson R, Erlanson P, Bodemar G et al.: The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. Br J Clin Pharmacol 13: 163, 1982

    PubMed  CAS  Google Scholar 

  479. Bjaeldager PA, Jensen JB, Nielsen LP, Larsen NE, Hvidberg EF: Pharmacokinetics of cimetidine in patients undergoing hemodialysis. Nephron 34: 159, 1983

    PubMed  CAS  Google Scholar 

  480. Krishna DR, Klotz U: Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential. Clin Pharmacokinet 15: 205, 1988

    PubMed  CAS  Google Scholar 

  481. Echizen H, Ishizaki T: Clinical pharmacokinetics of famotidine. Clin Pharmacokinet 21: 178, 1991

    PubMed  CAS  Google Scholar 

  482. Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H: Pharmacokinetics and dynamics of famotidine in patients with renal failure. Br J Clin Pharmacol 26: 315, 1988

    PubMed  CAS  Google Scholar 

  483. Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR: Disposition of famotidine in renal insufficiency. J Clin Pharmacol 27: 782, 1987

    PubMed  CAS  Google Scholar 

  484. Price AH, Brogden RN: Nizatidine: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 36: 521, 1988

    PubMed  CAS  Google Scholar 

  485. Saima S, Echizen H. Yoshimoto K, Ishizaki T: Hemofiltrability of histamine H2-receptor antagonist, nizatidine, and its metabolites in patients with renal failure. J Clin Pharmacol 33: 324, 1993

    PubMed  CAS  Google Scholar 

  486. Comstock TJ, Sica DA, Harford A, Eshelman F: Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis. Nephron 52: 15, 1989

    PubMed  CAS  Google Scholar 

  487. Grant SM, Langtry HD, Brogden RN: Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 37: 801, 1989

    PubMed  CAS  Google Scholar 

  488. Meffin PJ, Grgurinovich N, Brooks PM, Miners JO, Cochran M, Stranks G: Ranitidine disposition in patients with renal impairment. Br J Clin Pharmacol 16: 731. 1983

    PubMed  CAS  Google Scholar 

  489. Zech PY, Chau NP, Pozet N, Labeeuw M, Hadj-Aissa A: Ranitidine kinetics in chronic renal impairment. Clin Pharmacol Ther 34: 667, 1983

    Article  PubMed  CAS  Google Scholar 

  490. Barradell LB, Faulds D, McTavish D: Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 44: 225, 1992

    PubMed  CAS  Google Scholar 

  491. Jones JB, Bailey RT: Misoprostol: a prostaglandin E1 analog with antisecretory and cytoprotective properties. DICP, Ann Pharmacother 23: 276, 1989

    CAS  Google Scholar 

  492. Howden CW: Clinical pharmacology of omeprazole. Clin Pharmacokinet 20: 38, 1991

    PubMed  CAS  Google Scholar 

  493. Naesdal J, Andersson T, Bodemar G et al.: Pharmacokinetics of [14C]omeprazole in patients with impaired renal function. Clin Pharmacol Ther 40: 344, 1986

    Article  PubMed  CAS  Google Scholar 

  494. Burgess E, Muruve D, Audette R: Aluminum absorption and excretion following sucralfate therapy in chronic renal insufficiency. Am J Med 92: 471, 1992

    PubMed  CAS  Google Scholar 

  495. Roxe DM, Mistovich M, Barch DH: Phosphate-binding effects of sucralfate in patients with chronic renal failure. Am J Kidney Dis 13: 194, 1989

    PubMed  CAS  Google Scholar 

  496. Eadie MJ: Anticonvulsant drugs. An update. Drugs 27: 328, 1984

    PubMed  CAS  Google Scholar 

  497. Bertilsson L, Tomson T: Clinical pharmacokinets and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide: an update. Clin Pharmacokinet 11: 177, 1986

    PubMed  CAS  Google Scholar 

  498. Lee CS, Wang LH, Marbury TC, Bruni J, Peschalski RJ: Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis. Clin Toxicol 17: 429, 1980

    PubMed  CAS  Google Scholar 

  499. Marbury TC, Lee CS, Perchalski RJ, Wilder BJ. Hemodialysis clearance of ethosuximide in patients with chronic renal disease. Am J Hosp Pharm 38: 1757, 1981

    PubMed  CAS  Google Scholar 

  500. Dasgupta A, Abu-Alfa A: Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Am J Clin Pathol 98: 19, 1992

    PubMed  CAS  Google Scholar 

  501. Czajka PA, Anderson WH, Christoph RA, Banner W Jr: A pharmacokinetic evaluation of peritoneal dialysis for phenytoin intoxication. J Clin Pharmacol 20: 565, 1980

    PubMed  CAS  Google Scholar 

  502. Lee CS, Marbury TC, Perchalski RT, Wilder BJ: Pharmacokinetics of primidone elimination by uremic patients. J Clin Pharmacol 22: 301, 1982

    PubMed  CAS  Google Scholar 

  503. Brewster D, Muir NC: Valproate plasma protein binding in the uremic condition. Clin Pharmacol Ther 27: 76, 1980

    Article  PubMed  CAS  Google Scholar 

  504. Zaccara G, Messori A, Moroni F: Clinical pharmacokinetics of valproic acid-1988. Clin Pharmacokinet 15: 367, 1988

    PubMed  CAS  Google Scholar 

  505. Cedarbaum JM: Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 13: 141, 1987

    PubMed  CAS  Google Scholar 

  506. Yen KC, August TF, Bush DF et al.: Pharmacokinetics and bioavailability of sinemet CR: ta summary of human studies. Neurology 39(Suppl 2): 25, 1989

    Google Scholar 

  507. Burke RE, Fahn S: Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol 18: 35, 1985

    PubMed  CAS  Google Scholar 

  508. Hande K, Noone RM, Stone WJ: Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 76: 47, 1984

    PubMed  CAS  Google Scholar 

  509. Murrel GA, Rapeport WG: Clinical pharmacokinetics of allopurinol. Clin Pharmacokinet 11: 343, 1986

    Google Scholar 

  510. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW: Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 18: 264, 1991

    PubMed  CAS  Google Scholar 

  511. Levy M, Spino M, Read SE: Colchicine: a state of the art review. Pharmacotherapy 11: 196, 1991

    PubMed  CAS  Google Scholar 

  512. Cunningham RF, Israili ZH, Dayton PG: Clinical pharmacokinetics of probenecid. Clin Pharmacokinet 6: 135, 1981

    PubMed  CAS  Google Scholar 

  513. Verbeeck RK, Blackburn JL, Loewen GR: Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 8: 297, 1983

    PubMed  CAS  Google Scholar 

  514. Todd PA, Sorkin EM: Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 35: 244, 1988

    PubMed  CAS  Google Scholar 

  515. Eriksson LO, Wahlin-boll E, Odar-Cederlof I, Lindholm L, Melander A: Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal. Eur J Clin Pharmacol 36: 165, 1989

    Google Scholar 

  516. Balfour JA, Buckley MM: Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. Drugs 42: 274, 1991

    PubMed  CAS  Google Scholar 

  517. Cefali EA, Poynor WJ, Sica D, Cox S: Pharmacokinetic comparison of flurbiprofen in end-stage renal disease subjects and subjects with normal renal function. J Clin Pharmacol 31: 808, 1991

    PubMed  CAS  Google Scholar 

  518. Albert KS, Gernaat CM: Pharmacokinetics of ibuprofen. Am J Med 77: 40, 1984

    PubMed  CAS  Google Scholar 

  519. Skoutakis VA, Acchiardo SR, Carter CA, Wojciechowski NJ, Straun AB, Meyer MC: Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease. Drug Intell Clin Pharm 20: 956, 1986

    PubMed  CAS  Google Scholar 

  520. Williams RL, Upton RA: The clinical pharmacology of ketoprofen. J Clin Pharmacol 28(Suppl 12): S13, 1988

    Google Scholar 

  521. Brocks DR, Jamali F: Clinical pharmacokinetics of ketorolac tromethamine. Clin Pharmacokinet 23: 415, 1992

    PubMed  CAS  Google Scholar 

  522. Todd PA, Clissold SP: Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states. Drugs 40: 91, 1990

    PubMed  CAS  Google Scholar 

  523. Verbeeck RK, Richardson CJ, Blocka KL: Clinical pharmacokinetics of piroxicam. J Rheumatol 13: 789, 1986

    PubMed  CAS  Google Scholar 

  524. Ravis WR, Diskin CJ, Campagna KD, Clark CR, McMillan CL: Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure. J Clin Pharmacol 33: 527, 1993

    PubMed  CAS  Google Scholar 

  525. Chaffman M, Brogden RN, Heel RC, Speight TM, Avery GS: Auranofin: a preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis. Drugs 27: 378, 1984

    PubMed  CAS  Google Scholar 

  526. Blocka KL, Paulus HE, Furst DE: Clinical pharmacokinetics of oral and injectable gold compounds. Clin Pharmacokinet 11: 133, 1986

    PubMed  CAS  Google Scholar 

  527. Levy NB: Psychopharmacology in patients with renal failure. Int J Psychiatr Med 20: 325, 1990

    Article  CAS  Google Scholar 

  528. Preskorn SH, Othmer SC: Evaluation of bupropion hydrochloride: the first of a new class of atypical anti-depressants. Pharmacotherapy 4: 20, 1984

    PubMed  CAS  Google Scholar 

  529. Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL, Lemberger L: Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 36: 138, 1984

    Article  PubMed  CAS  Google Scholar 

  530. Benfield P, Heel RC, Lewis SP: Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32: 481, 1986

    PubMed  CAS  Google Scholar 

  531. Christensen JH, Andreasen F, Jansen J: Pharmacokinetics and pharmacodynamics of thiopental in patients undergoing renal transplantation. Acta Anaesthesiol Scand 27: 513, 1983

    PubMed  CAS  Google Scholar 

  532. Garzone PD, Kroboth PD: Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 16: 337, 1989

    PubMed  CAS  Google Scholar 

  533. Schmith VD, Piraino B, Smith RB, Kroboth PD: Alprazolam in end-stage renal disease: I. Pharmacokinetics. J Clin Pharmacol 31: 571, 1991

    PubMed  CAS  Google Scholar 

  534. Ochs HR, Rauh HW, Greenblatt DJ: Clorazepate dipotassium and diazepam in renal insufficiency: serum concentrations and protein binding of diazepam and desmethyldiazepam. Nephron 37: 100, 1984

    PubMed  CAS  Google Scholar 

  535. Greenblatt DJ, Shader RI, MacLeod SM, Sellers EM: Clinical pharmacokinetics of chlordiazepoxide. Clin Pharmacokinet 3: 381, 1978

    PubMed  CAS  Google Scholar 

  536. Morrison G, Chiang ST, Koepke HH, Walker BR: Effect of renal impairment and hemodialysis on lorazepam kinetics. Clin Pharmacol Ther 35: 646, 1984

    Article  PubMed  CAS  Google Scholar 

  537. Vinik HR, Reves JG, Greenblatt DJ, Abernethy DR, Smith LR: The pharmacokinetics of midazolam in chronic renal failure patients. Anesthesiology 59: 390, 1983

    PubMed  CAS  Google Scholar 

  538. Ochs HR, Oberem U, Greenblatt DJ: Nitrazepam clearance unimpaired in patients with renal insufficiency. J Clin Psychopharmacol 12: 183, 1992

    PubMed  CAS  Google Scholar 

  539. Greenblatt DJ, Murray TG, Audet PR, Locniskar A, Koepke HH, Walker BR: Multiple-dose kinetics and dialyzability of oxazepam in renal insufficiency. Nephron 34: 234, 1983

    PubMed  CAS  Google Scholar 

  540. Ankier SI, Goa KL: Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia. Drugs 35: 42, 1988

    Article  PubMed  CAS  Google Scholar 

  541. Kroboth PD, Smith RB, Sorkin MI et al.: Triazolam protein binding and correlation with alpha-1 acid glycoprotein concentration. Clin Pharmacol Ther 36: 379, 1984

    Article  PubMed  CAS  Google Scholar 

  542. Roth T, Roehrs TA, Zorick FJ: Pharmacology and hypnotic efficacy of triazolam. Pharmacotherapy 3: 137, 1983

    PubMed  CAS  Google Scholar 

  543. Loo JC, Midha KK, McGilveray IJ: Pharmacokinetics of chlorpromazine in normal volunteers. Communications in Psychopharmacology 4: 121, 1980

    PubMed  CAS  Google Scholar 

  544. Taylor G, Houston JB, Shaffer J, Mawer G: Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man. Br J Clin Pharmacol 15: 287, 1983

    PubMed  CAS  Google Scholar 

  545. Lieberman JA, Cooper TB, Suckow RF et al.: Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin Pharmacol Ther 37: 301, 1985

    Article  PubMed  CAS  Google Scholar 

  546. Sandoz M, Vandel S, Vandel B et al.: Metabolism of amitriptyline in patients with chronic renal failure. Eur J Clin Pharmacol 26: 227, 1984

    PubMed  CAS  Google Scholar 

  547. Tasset JJ, Singh S, Pesce AJ: Evaluation of amitriptyline pharmacokinetics during peritoneal dialysis. Ther Drug Monit 7: 255, 1985

    PubMed  CAS  Google Scholar 

  548. McTavish D, Benfield P: Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 39: 136, 1990

    PubMed  CAS  Google Scholar 

  549. DeVane CL, Savett M, Jusko WJ: Desipramine and 2-hydroxy-desipramine pharmacokinetics in normal volunteers. Eur J Clin Pharmacol 19: 61, 1981

    PubMed  CAS  Google Scholar 

  550. Faulkner RD, Senekjian HO, Lee CS: Hemodialysis of doxepin and desmethyldoxepin in uremic patients. Artif Organs 8: 151, 1984

    PubMed  CAS  Google Scholar 

  551. Potter WZ, Calil HM, Sutfin TA et al.: Active metabolites of imipramine and desipramine in man. Clin Pharmacol Ther 31: 393, 1982

    Article  PubMed  CAS  Google Scholar 

  552. Dawling S, Lynn K, Rosser R, Braithwaite R: Nortriptyline metabolism in chronic renal failure: metabolite elimination. Clin Pharmacol Ther 32: 322, 1982

    Article  PubMed  CAS  Google Scholar 

  553. Ziegler VE, Biggs JT, Wylie LT et al.: Protriptyline kinetics. Clin Pharmacol Ther 23: 580, 1978

    PubMed  CAS  Google Scholar 

  554. Caccia S, Vigano GL, Mingardi G et al.: Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. Clin Pharmacokinet 14: 171, 1988

    PubMed  CAS  Google Scholar 

  555. Fitton A, Heel RC: Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40: 722, 1990

    PubMed  CAS  Google Scholar 

  556. Froemming JS, Lam YW, Jann MW, Davis CM: Pharma-cokinetics of haloperidol. Clin Pharmacokinet 17: 396, 1989

    PubMed  CAS  Google Scholar 

  557. Singer I: Lithium and the kidney. Kidney Int 19: 374, 1981

    PubMed  CAS  Google Scholar 

  558. Luisier PA, Schultz P, Dick P: The pharmacokinetics of lithium in normal humans: expected and unexpected observations in view of basic kinetic principles. Pharmacopsychiatry 20: 232, 1987

    PubMed  CAS  Google Scholar 

  559. Mahoney G, Wolfram KM, Cochetto D, Bjorsson TD: Dipyridamole kinetics. Clin Pharmacol Ther 31: 330, 1982

    Article  Google Scholar 

  560. Kandrotas RJ: Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 22: 359, 1992

    PubMed  CAS  Google Scholar 

  561. Grierson DS, Bjornsson TD: Pharmacokinetics of streptokinase in patients based on amidolytic activator complex activity. Clin Pharmacol Ther 41: 304, 1987

    Article  PubMed  CAS  Google Scholar 

  562. Pedersen AK, Jakobsen P, Kampmann JP, Hansen JM: Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone. Clin Pharmacokinet 7: 42, 1982

    Article  PubMed  CAS  Google Scholar 

  563. McTavish D, Faulds D, Goa KL: Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 40: 238, 1990

    PubMed  CAS  Google Scholar 

  564. Collen D, Lijnen HR, Todd PA, Goa KL: Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs 38: 346, 1989

    PubMed  CAS  Google Scholar 

  565. Holford NH: Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 11: 483, 1986

    PubMed  CAS  Google Scholar 

  566. Paton DP, Webster DR: Clinical pharmacokinetics of H1 — receptor antagonists (The antihistamines). Clin Pharmacokinet 10: 477, 1985

    PubMed  CAS  Google Scholar 

  567. Krstenansky PM, Cluxton RJ: Astemizole: a long-acting, nonsedating antihistamine. Drugs Intell Clin Pharm 21: 947, 1987

    CAS  Google Scholar 

  568. Richards DM, Brogden RM, Heel RC, Speight TM, Avery GS: Oxatomide: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 27: 210, 1984

    PubMed  CAS  Google Scholar 

  569. Carter CA, Wojciechowski NJ, Hayes JM, Skoutakis VA. Rickman LA: Terfenadine, a nonsedating antihistamine. Drug Intell Clin Pharm 19: 812, 1985

    PubMed  CAS  Google Scholar 

  570. Morgan DJ: Clinical pharmacokinetics of beta-agonists. Clin Pharmacokinet 18: 270, 1990

    PubMed  CAS  Google Scholar 

  571. Friedel HA, Brogden RN: Bitolterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease. Drugs 35: 22, 1988

    PubMed  CAS  Google Scholar 

  572. Lee CCU, Wang LH, Majeske BL, Marbury TC: Pharmacokinetics of dyphylline elimination by uremic patients. J Pharmacol Exp Ther 217: 340, 1981

    PubMed  CAS  Google Scholar 

  573. Bauer LA, Bauer SP, Blouin RA: The effect of acute and chronic renal failure on theophylline clearance. J Clin Pharmacol 22: 65, 1982

    PubMed  CAS  Google Scholar 

  574. Kradjan WA, Martin TR, Delaney CJ, Blair AD, Cutler RE: Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure. Nephron 32: 40, 1982

    PubMed  CAS  Google Scholar 

  575. Chan GL, Canafax DM, Johnson CA: The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy 7: 165, 1987

    PubMed  CAS  Google Scholar 

  576. Salemans J, Hoitsma AJ, De Abreu RA et al.: Pharmacokinetics of azathioprine and 6-mercaptopurine after oral administration of azathioprine. Clin Transplant 1: 217, 1987

    Google Scholar 

  577. Kawai S, Ichikawa Y, Homma M: Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure. J Clin Endocrinol Metal 60: 848, 1985

    Article  CAS  Google Scholar 

  578. Sherlock JE, Letteri JM: Effect of hemodialysis on methylprednisolone plasma levels. Nephron 18: 208, 1977

    PubMed  CAS  Google Scholar 

  579. Frey BM, Frey FJ: Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 19: 126, 1990

    PubMed  CAS  Google Scholar 

  580. Follath F, Wenk M, Vozeh S et al.: Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther 34: 638, 1983

    Article  PubMed  CAS  Google Scholar 

  581. Putcha L, Griffith DP, Feldman S: Pharmacokinetics of acetohydroxamic acid in patients with staghorn renal calculi. Eur J Clin Pharmacol 28: 439, 1985

    PubMed  CAS  Google Scholar 

  582. Boelaert JR, Fenves AZ, Coburn JW: Deferoxamine therapy and mucormycosis in dialysis patients: report of international registry. Am J Kidney Dis 18: 660, 1991

    PubMed  CAS  Google Scholar 

  583. Verpooten GA, D’Haese PC, Boelaert JR, Becaus I, Lamberts LV, De Broe ME: Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. Nephrol Dial Transplant 7: 931, 1992

    PubMed  CAS  Google Scholar 

  584. Silver MR, Kroboth PD: Pentoxifylline in end-stage renal disease. Drug Intell Clin Pharm 21: 976, 1987

    PubMed  CAS  Google Scholar 

  585. Ward A, Clissold SP: Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34: 50, 1987

    PubMed  CAS  Google Scholar 

  586. Reetze-Bonorden P, Böhler J, Keller E: Drug dosage in patients during continuous renal replacement therapy. Clin Pharmacokinet 24: 362, 1993

    PubMed  CAS  Google Scholar 

  587. Kroh UF, Dehne M, El Abed K, Feubner KD, Hofmann W, Lennartz H: Drug dosage during continuous hemofiltration: pharmacokinetics and practical implications, in Contrib Nephrol, Vol 93, edited by Sieberth HG, Mann H, Stummvoll HK, Basel, Karger, 1991, p 127

    Google Scholar 

  588. Goldman M, Vanherweghem J: Bacterial infections in chronic hemodialysis patients: epidemiologic and pathophysiologic aspects. Adv Nephrol Necker Hosp 19: 315, 1990

    PubMed  CAS  Google Scholar 

  589. Mailloux LU, Bellucci AG, Wilkes BM et al.: Mortality in dialysis patients: analysis of the causes of death. Am J Kidney Dis 18: 326, 1991

    PubMed  CAS  Google Scholar 

  590. Manian FA, Stone WJ, Alford RH: Adverse antibiotic effects associated with renal insufficiency. Rev Infect Dis 12: 236, 1990

    PubMed  CAS  Google Scholar 

  591. Gilbert DN: Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 35: 399, 1991

    PubMed  CAS  Google Scholar 

  592. Wood CA, Norton DR, Kohlhepp SJ et al.: The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis 158: 13, 1988

    PubMed  CAS  Google Scholar 

  593. Johnson CA, Zimmerman SW, Rogge M: The pharmacokinetics of antibiotics used to treat peritoneal dialysis-associated peritonitis. Am J Kidney Dis 4: 3, 1984

    PubMed  CAS  Google Scholar 

  594. Keane WF, Everett ED, Golper TA et al.: Peritoneal dialysis-related peritonitis treatment recommendations. 1993 update. Perit Dial Int 13: 14, 1993

    PubMed  CAS  Google Scholar 

  595. Humes HD: Aminoglycoside nephrotoxicity. Kidney Int 33: 900, 1988

    PubMed  CAS  Google Scholar 

  596. Cameron JS: Allergic interstitial nephritis: clinical features and pathogenesis. Q J Med 66: 97, 1988

    PubMed  CAS  Google Scholar 

  597. Shouval D, Ligumsky M, Ben-Ishay D: Effect of co-trimoxazole on normal creatinine clearance. Lancet i(8058): 244, 1978

    Google Scholar 

  598. Agodoa LY, Held PJ, Port FK: Causes of death, in US Renal Data System, USRDS 1993 Annual Data Report, Bethesda, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease. 1993, p 49

    Google Scholar 

  599. Parving HH, Smidt UM, Hommel E et al.: Effective anti-hypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 22: 188, 1993

    PubMed  CAS  Google Scholar 

  600. Castelli WP: Epidemiology of coronary heart disease: The Framingham Study. Am J Med 76: 4, 1984

    PubMed  CAS  Google Scholar 

  601. Fer MF, McKinney TD, Richardson RL, Hande RR, Oldham RK, Greco FA: Cancer and the kidney: renal complications of neoplasms. Am J Med 71: 704, 1981

    PubMed  CAS  Google Scholar 

  602. Narins RG, Carley M, Bloom EJ, Harrison DS: The nephrotoxicity of chemotherapeutic agents. Semin Nephrol 10: 556, 1990

    PubMed  CAS  Google Scholar 

  603. Adrogué HJ: Glucose homeostasis and the kidney. Kidney Int 42: 1266, 1992

    PubMed  Google Scholar 

  604. Alvestrand A, Mujagic M, Wajngot A, Efendic S: Glucose intolerance in uremic patients: the relative contributions of impaired β-cell function and insulin resistance. Clin Nephrol 31: 175, 1989

    PubMed  CAS  Google Scholar 

  605. Hager SR: Insulin resistance of uremia. Am J Kidney Dis 14: 272, 1989

    PubMed  CAS  Google Scholar 

  606. Wideröe TE, Smeby LC, Berg KJ, Jorstad S, Svartas TM: Intraperitoneal (125I) insulin absorption during intermittent and continuous peritoneal dialysis. Kidney Int 23: 22, 1983

    PubMed  Google Scholar 

  607. Attma PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 21: 573, 1993

    Google Scholar 

  608. Cheung AK, Wu LL, Kablitz C, Leypoldt JK: Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis 22: 271, 1993

    PubMed  CAS  Google Scholar 

  609. Joven J, Vilella E, Ahmad S, Cheung MC, Brunzell JD: Lipoprotein heterogeneity in end-stage renal disease. Kidney Int 43: 410, 1993

    PubMed  CAS  Google Scholar 

  610. Golper TA: Therapy for uremic hyperlipidemia. Nephron 38: 217, 1984

    PubMed  CAS  Google Scholar 

  611. D’Amico G, Gentile MG: Treatment of hyperlipidemia in human renal disease. Miner Electrolyte Metab 19: 196, 1993

    PubMed  CAS  Google Scholar 

  612. Orwoll ES: The milk-alkali syndrome: current concepts. Ann Intern Med 97: 242, 1982

    PubMed  CAS  Google Scholar 

  613. Fraser CL, Arieff AI: Nervous system complications in uremia. Ann Intern Med 109: 143, 1988

    PubMed  CAS  Google Scholar 

  614. Clive DM, Stoff FS: Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 310: 563, 1984

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Medicine, Mail Slot 501 Department of Internal Med./Div. of Nephrology, University of Arkansas, 4301 West Markham Street, Little Rock, AR, 72205, USA

    Thomas A. Golper M.D.

  2. Asst. Professor of Pharmacy Practice College of Pharmacy, University of Arkansas for Med. Sciences, Little Rock, AR, 72205, USA

    Michael A. Marx Ph.D.

  3. Division of Nephrology and Hypertension, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road L 455, Portland, OR, 97201, USA

    Cathryn Shuler M.D. & William M. Bennett M.D., Ph.D.

Authors
  1. Thomas A. Golper M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael A. Marx Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cathryn Shuler M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William M. Bennett M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

C. Jacobs C. M. Kjellstrand K. M. Koch J. F. Winchester

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Kluwer Academic Publishers

About this chapter

Cite this chapter

Golper, T.A., Marx, M.A., Shuler, C., Bennett, W.M. (1996). Drug Dosage in Dialysis Patients. In: Jacobs, C., Kjellstrand, C.M., Koch, K.M., Winchester, J.F. (eds) Replacement of Renal Function by Dialysis. Springer, Dordrecht. https://doi.org/10.1007/978-0-585-36947-1_30

Download citation

  • DOI: https://doi.org/10.1007/978-0-585-36947-1_30

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-0-7923-3610-5

  • Online ISBN: 978-0-585-36947-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation